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chapter I 
RATIONALL Of- THESIS 
Immunotherapy with Bacillus Calmette-Guérin (BCG) for patients with 
bladder cancer has been used since 1976.' Bacillus Calmette-Guérin is a 
vaccine containing a live attenuated organism originally developed at the 
Pasteur Institute of Lille. 
In order to use BCG effectively and safely, it is necessary to understand 
what this vaccine contains, the effect it exerts on the bladder, how to select 
patients appropriately, how it should be administered and what the results 
of therapy are likely to be. Most of these aspects of BCG are still unclear, due 
to the complexity of the immune response to these bacilli which involves 
stimulation of both cellular and humoral immune reactions. 
The majority of patients tolerate BCG-instillations well, but adverse reactions 
can and do occur. The side effects of BCG-therapy vary from mild malaise 
and fever till in rare instances life-threatening or fatal sepsis.2 Because of this 
toxicity, the indication for intravesical immunotherapy with BCG has to be 
very strict. 
Although BCG-immunotherapy has proved to be very effective in the 
prophylaxis and treatment of superficial bladder tumors and carcinoma in 
situ of the bladder,3 still some patients do not ultimately benefit from this 
therapy and will show recurrences4 and progression5 of their bladder cancer. 
To improve the results of intravesical BCG-immunotherapy three aspects are 
of interest: the toxicity, the efficacy and the indication of the therapy. 
The aim of this thesis was to get more insight into the effector mechanism of 
the BCG nonspecific immunotherapy for patients with superficial bladder 
cancer, to improve this therapy with regard to toxicity, antitumor efficacy 
and the indication. 
Chapter 2 describes the consensus and controversies of BCG-therapy. From 
this review it becomes clear that little is known about the effector mechanism 
of BCG-treatment and that more research is needed in this field. To get more 
insight into the effector mechanisms of intravesical BCG-therapy, the effects 
of immunological reactions observed in the urine of patients treated with 
intravesical BCG is evaluated in chapter 3. Also, the possible effector mecha-
nisms of this therapy in patients with bladder cancer are discussed in this 
chapter. 
} 
BCG is thought one of the most effective agents for the treatment of patients 
with superficial bladder cancer.2 The efficacy of intravesical chemotherapy 
with Mitomycin-C in patients with superficial bladder cancer has been 
proven.6'7 To compare the results of intravesical immunotherapy using two 
different BCG-strams, with intravesical chemotherapy using Mitomycin-C, a 
prospective randomized trial is described in chapter 4. In this chapter the 
efficacy of intravesical BCG-Tice and BCG-RIVM administration and intra-
vesical Mitomycin-C administration is evaluated. 
Impairment of the toxicity of BCG will result in an improvement of BCG-
therapy in patients with bladder cancer. Antituberculostatic drugs, like 
Isoniazid can prophylactically be administered to decrease the toxicity of 
BCG-treatment.8 It is, however, unknown if these drugs will impair the 
immunologic response of BCG and by that the antitumor effect. In the guinea 
pig Isoniazid seems to impair the local immunological response.9 This is the 
rationale to study the effects of Isoniazid prophylaxis in man. Chapter 5 
reports the effects of oral Isoniazid administration on the immunological 
response of intravesical BCG-therapy in man. 
To evaluate the influence of prophylactic Isoniazid administration on the 
toxicity and efficacy of intravesical BCG-therapy in patients with superficial 
bladder cancer, the European Organisation for Research and Treatment of 
Cancer-study 30911 has been designed. In this study the three treatments 
arms: intravesical BCG and intravesical BCG + prophylactic Isoniazid and 
intravesical chemotherapy with epirubicin are compared. The interim analy-
sis of the toxicity data available from patients treated with BCG and BCG + 
Isoniazid in this study is reported in chapter 6 of these thesis. 
Improvement of BCG therapy can also be achieved by a more defined indica-
tion. With a combination of several conventional prognostic factors, like 
tumor stage, grade, number of tumors and previous recurrence rates, the risk 
for tumor recurrence and thus progression can be estimated.10 However, these 
factors do not accurately predict the clinical behaviour of the malignant 
proces.11 The evaluation of new tumor markers, like p53 and E-cadhenn 
expression may have prognostic value for the individual patient.12'13 In 
chapter 7 the prognostic value of p53 and E-cadhenn expression are described 
in patients with superficial bladder cancer. 
This thesis concludes with chapter 8 in which the major conclusions are 
discussed. 
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chapter 2 
ABSTRACT 
In this overview, Bacillus Calmette-Guérin (BCG) immunotherapy in super-
ficial bladder cancer items are discussed on which consensus has been reached 
and on which controversies exist. The evaluation of the optimal route of 
administration has shown that intravesical instillation of BCG alone is 
accepted as the best route of administration. In searching for the appropriate 
BCG-strain, the analysis of the results of 7 substrains has made clear that no 
particular strain has shown superiority over others. In finding the optimal 
treatment schedule there is strong evidence that maintenance therapy is 
superior to induction therapy alone. No consensus has been reached about 
the optimal dose for BCG-therapy nor about how the toxicity of BCG-treat-
ment can be reduced. Although some reports have stated that BCG-immuno-
therapy is superior to chemotherapy for the treatment of patients with 
superficial bladder cancer, more data are needed to prove this statement. 
In conclusion: although BCG has been proven to be very effective in the 
treatment of patients with superficial bladder cancer, it is certainly not a 
panacea for all patients with superficial bladder cancer. 
9 
INTRODUCTION 
Bacillus Calmette-Guénn (BCG) has been used for over 15 years now as an 
adjuvant treatment for superficial bladder cancer. At the start of this new 
therapy in 1976 by Morales, a number of controversies existed. It was 
unknown which dose was optimal, which treatment scheme should be used 
and whether there was an optimal BCG-strain. N o consensus existed about 
the appropriate route of administration, about which tumors should be 
treated and which not. There were problems about the toxicity of BCG 
intravesical therapy and how to deal with it. The working mechanism of BCG 
was not understood. At present, non specific immunotherapy with BCG for 
superficial bladder cancer is considered one of the most efficacious treat-
ments. It is probably the most widely used and most successful immunothe-
rapy in man. This article describes the items on which we have reached 
consensus as well as the problems which still are unsolved or on which 
controversies still exist. It describes the evolution of BCG-therapy over the 
last 15 years. 
Calmette and Guérin developed in 1908 a vaccine for the prevention of 
tuberculosis. This widespread contagious disease had caused millions of 
deaths at that time. These 2 French co-workers were working with a highly 
virulent strain of the bovine tubercle bacillus. By transplanting it from culture 
to culture the tubercle bacillus was gradually losing its noxious charac-
teristics.1 Calmette and Guérin spent 13 consecutive years and 231 transplan-
tations to tame the bovine bacillus. It had become completely harmless but 
its antigenic properties were unimpaired. Since 1921, over 500 million 
vaccinations with BCG to prevent tuberculosis have been performed. 
In the 1930s, Rosenthal2 reported that when the vaccine was administered 
to animals by various routes, a local and generalized stimulation of the 
immune apparatus could be observed. This stimulation led to the eradication 
of several tumors in animals. 
The research group of Zbar and Rapp3 investigated the basic principles 
for successful nonspecific active immunotherapy in a guinea pig hepatocar-
cinoma. By intratumoral injection of BCG, not only the primary tumor but 
also metastases in the regional lymph nodes were eradicated. Furthermore, 
the existence of tumor immunity could be demonstrated as BCG-cured 
animals rejected a second tumor cell challenge. 
In man, immunotherapy with BCG was first used by Mathé et al.4 in the 
treatment of acute lymphoblastic leukaemia. 
10 
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Morales et al.s were the first to investigate the efficacy of BCG administered 
both as an intradermal application and intravesically diluted in saline in 
patients with superficial transitional urinary bladder tumors. This therapy 
turned out to be very successful and at present urologists all over the world 
are using it. However, BCG-therapy has its indications and also its limits. 
BCG has its place together with intravesical chemotherapy but does not 
replace it completely. BCG is certainly not a panacea for every patient with 
superficial bladder cancer. Since this therapy seems to have more side effects 
than intravesical chemotherapy, a careful risk-to-benefit analysis has to be 
made about which patient should receive BCG and which not. 
THE ROUTE OF ADMINISTRATION 
Five different routes of BCG-administration for the treatment of superficial 
bladder cancer have been used so far: 
- percutaneous administration 
- intralesional injection 
- oral administration 
- intravesical instillation combined with percutaneous administration 
- intravesical instillation alone 
Percutaneous administration of BCG in superficial bladder cancer was inves-
tigated by Martinez-Pineiro and Muntanola.6 7 Per week, 10 scarifications 
measuring 5 cm in length were administered. At each treatment 0.5 ml of 
lyophilized Pasteur BCG vaccine, containing 300 mg/ml was used. Only 7 
patients were treated and many variable factors (different periods of treat-
ment, patients with or without residual bladder tumors) made it impossible 
to estimate the value of this intensive treatment but an antitumor effect was 
observed. Intralesional administration was performed by the same authors in 
two patients by injecting 37.5 mg of BCG into their bladder tumor. One 
patient developed a serious hypersensitivity reaction, resulting in an allergic 
shock. Thereafter, this way of administration was abolished. 
The antitumor effect of oral administration of BCG was studied by several 
investigators (Lamm personal communications 1987 and 1988). Netto and 
Lemos8 treated 10 patients with muscle-invasive bladder cancer using fresh 
BCG of the Moreau strain in high doses. A complete response was obtained 
in 7 patients. Lamm (personal communications 1978, 1988) used oral 
administration of the Tice-BCG-strain in muscle invasive bladder cancer in 
patients who could not be treated by radiation of cystectomy. Although tumor 
11 
regression was observed, the results were less impressive compared with those 
of Netto and Lemos.8 Lamm et al.9 also investigated the effect of orally 
administered BCG (200 mg Tice-BCG, 3 times per week) in superficial 
bladder tumors. No measurable antitumor effect, however, was observed in 
patients treated this way. 
The most thoroughly investigated route of administration is the intravesi-
cal instillation, initially combined with percutaneous administration. Mora-
les et al.5 developed an empirically based therapeutic scheme which remained 
the treatment modality in superficial bladder cancer for many years. They 
instilled BCG in a watery solution in the bladder once weekly for 6 consecu-
tive weeks. At the same time, BCG was administered percutaneously at the 
anterior surface on the thigh by a multiple puncture apparatus After 10 years 
of experience, reviewing his results, Morales and Nickel10 reported a complete 
response in 50% of the patients using BCG as a prophylactic treatment after 
transurethral resection. In 58% of patients with residual disease and in 77% 
of patients with carcinoma in situ, complete response was achieved. Two 
prospective randomized clinical trials,11, 12 using the Morales treatment 
schedule, were conducted in the USA. Responses were in the same range as 
those obtained by Morales. Herret al.13'14 used intravesical and percutaneous 
BCG for the treatment of carcinoma in situ. A complete response was noted 
in 65% of the patients. 
Excellent results of intravesical BCG-instillation without percutaneous 
administration were reported by Brosman.15- 16 In a randomized study, 
patients were treated either with Thiotepa instillations or with BCG-instilla-
tions; BCG was administered intravesically weekly for 12 consecutive weeks, 
followed by instillations every 2 weeks for 3 months and thereafter every 
month until a recurrent tumor developed or the patient had been treated for 
a total period of 2 years. No recurrences have been observed in BCG-treated 
group, while 40% in the Thiotepa group suffered from recurrences. 
Treating carcinoma in situ, 94% of the patients were rendered free of 
tumor.17 Brosman15 16 stated that patients do not require presensitization or 
continued intradermal inoculations of BCG as he observed that all his 
patients, when treated with intravesical instillations alone, converted from a 
negative PPD skin reaction to a positive one after 9 instillations. A problem 
in these studies was the increasing toxicity of the prolonged instillation 
treatment. 
At the moment, percutaneous supportive inoculation has been abandoned. 
It is considered as not essential for the antitumor effect of BCG-immunothe-
rapy in superficial bladder cancer, but the value of percutaneous administra-
12 
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non has not been intensely investigated. Thus, at the moment, intravesical 
administration of BCG alone is accepted in most centers to be the best route 
of administration in treating patients with superficial transitional cell carci-
noma of the urinary bladder. 
APPROPRIATE STRAIN 
Originally all of the known BCG-strains are derived from the Pasteur strain 
developed by Calmette and Guérin. From the 1930s on, cultures of the Pasteur 
strain were imported in several countries all over the world. Mostly they were 
exported to the various National Institutes for the development of antituber-
culous vaccines. By culturing from year to year substrains were obtained 
which showed resemblance but also differences with the original Pasteur 
strain in genetical and immunological properties. Comparative studies of 
different strains have been performed for several animal tumor models but 
for superficial bladder cancer very few studies have been carried out. The 
efficacy of BCG depends on at least two factors: the number of bacilli and 
the viability. The viability is the ability of the bacilli to multiply in vivo. The 
effect of BCG viability on treatment results was investigated for superficial 
bladder cancer by Kelley et al. in 1985.17 In the early 1980s, marked 
differences were noted between different strains and even between lots of 
BCG of the same strain. The number of culturable particles ranged from 5 χ 
IO6 to 1 χ IO12 per ampule. 
At present, all manufacturers are able to deliver a product with a relative 
constant quality, viability, and number of living microorganisms. However, 
since BCG is a living product, exact measures and limitations are requested 
to store and to use BCG. 
So far, the results of 7 substrains used for immunotherapy in superficial 
bladder cancer have been published. These preparations are Pasteur (France), 
Armand-Frappier (Canada), Tice (USA), Connaught (Canada), Evans (UK), 
Moreau (Brasil) and RIVM (The Netherlands). In the meantime, countries in 
Eastern Europe and in Asia have begun to use their own BCG substrains as 
well. 
In culturing BCG bacilli, the mycobacteria usually are grown as a pellicle 
on the surface of a liquid medium. At harvesting, the pellicle is ground in a 
ball mill to a paste. The final product contains not only living BCG bacilli 
but also dead microorganisms and subcellular debris. It is still unknown 
whether the debris and crushed bacilli play a role in the efficacy of BCG 
against superficial bladder tumors. 
Π 
There is another method of growing the bacteria in a so-called homogene­
ously stirred deep culture system. This culture method results in a relatively 
high ratio of viable organisms and a small quantity of subcellular debris and 
dead bacilli. After both methods of culture, the vaccines are harvested and 
lyophihzed. Most of the BCG preparations are surface cultures. Evans strain 
and the Dutch RIVM-strain are produced according to the homogeneous 
culture method. 
In 1988, a prospective randomized study comparing the efficacy of BCG-
RIVM versus Mitomycin-C was reported by Debruyne et al..18 At that time 
it was the first study reported in which BCG had been compared with 
Mitomycin-C. There was no difference in efficacy between the two drugs but 
it must be stated that the treatment schedule was different for the two arms. 
BCG patients were treated with a 6-week schedule while Mitomycin-C 
patients received a 6 months schedule. The results had led to the assumption 
that the Dutch BCG-RIVM might be inferior to other strains for two reasons. 
Firstly, the efficacy of BCG-RIVM was not higher than of a chemotherapeutic 
agent (Mitomycin-C) and secondly, the side effects reported seemed less 
significant compared to other strains. 
To investigate the quality of BCG-RIVM, the Dutch Southeast Coopera­
tive Urological Group decided to embark upon a three-arm prospective 
randomized trial in which BCG-RIVM, BCG-Tice and Mitomycin-C were 
com- pared. This was the first prospective randomized study in the world in 
which two BCG-strains were compared with Mitomycin-C in patients with 
primary or recurrent superficial bladder tumors, including carcinoma in situ. 
Therapeutic regimens were as follows: after complete transurethral resection 
of all visible tumors in the Mitomycin-C group, 30 mg Mitomycin-C in 50 
ml saline was instilled once a week for 4 weeks and thereafter once a month 
for a total of 6 months. In the BCG groups 5 χ IO8 colony forming units in 
50 ml saline of Tice respectively RIVM strain were instilled once a week for 
6 consecutive weeks. The median follow up is 36 months (range 2-81). The 
analysis of efficacy for the papillary tumors shows that Mitomycin-C and 
BCG-RIVM treatments were equally effective (p=0.53), BCG-Tice was less 
effective than BCG-RIVM and Mitomycin-C (p = 0.07 respectively ρ = 0.01). 
The side effects of the BCG-strains were comparable, both locally and 
systemically 3 3 
As there is only one prospective study with sufficient patient numbers 
reported, more studies are needed to investigate whether there is an optimal 
BCG-strain. 
14 
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THE OPTIMAL TREATMENT SCHEDULE 
Basically two different instillation schedules have been used so far. Morales 
started with a so-called induction scheme of 6 consecutive weekly instilla-
tions. The second scheme does comprise the 6-week induction course but is 
followed by repeated instillations during months up to 3 years although in 
the meantime the patient is free of tumor. The theory behind these repeated 
instillations is the assumption that these "booster" instillations evoke a 
renewed immune response against the possibly developing bladder tumors in 
the patient. This instillation scheme that has been used most frequently in 
large prospective trials in the USA is the so called "maintenance"-scheme.19 
In this scheme, 6 weekly instillations are administered followed by 3 conse-
cutive weekly instillations at 3 months, at 6 months and thereafter every 6 
months up to 36 months. This means that a patient who stays tumor free 
after the initial resection will receive a total of 27 instillations in a period of 
3 years. Few studies have been performed to investigate the efficacy of a 6-
week schedule versus maintenance treatment. Hudson et al.20 reported no 
difference in efficacy between a 6-week schedule and maintenance therapy 
but prolongation of toxicity was observed with maintenance BCG-therapy. 
The series of 42 patients investigated, however, was small. 
The effect of repeated 6-week courses, after failure of the first induction 
course, was also investigated by Catalona et al..21 Of 100 consecutive patients 
with superficial bladder cancer treated with 6 weeks of BCG, 44 became free 
of tumor. Of 49 patients treated with a second course of BCG, 19 were 
consequently rendered free of tumor. However, among patients who had 
failed 2 or more courses of BCG-therapy the risk of invasive (30%) or 
metastatic (50%) cancer exceeded the prospects for eradicating the superficial 
tumors (20%) with further therapy. 
The largest study comparing 6 weeks of BCG with a maintenance schedule 
of BCG has been carried out by the South West Oncology Group.22,23 After 
an interim analysis of 391 patients randomized between non-maintenance 
versus maintenance, a significant superiority was found in favor for mainte-
nance therapy. This was observed for 270 patients with Ta and Tl tumors 
(p=0.0001) but also for 121 patients with carcinoma in situ (p=0.04). 
Thus, there is strong evidence that maintenance therapy following successful 
induction therapy provides better protection against recurrences than induc-
tion therapy alone. 
15 
Regarding the results of the reported literature, it can be concluded that of 
the different instillation schemes used so far, maintenance BCG-immunothe-
rapy is superior. 
ADVERSE EFFECTS OF BCG 
Compared to intravesical chemotherapy, instillations with BCG provoke 
more local and systemic side effects. In addition to the commonly induced 
granulomatous inflammatory reactions in the bladder, which produce irrita-
tive symptoms, BCG-therapy may cause systemic side effects varying from 
mild malaise and fever to, in rare instances, life threatening or fatal sepsis. 
Without doubt these possible side effects have led to the decision of many 
urologists not to use BCG in every patient who needs intravesical instillation 
therapy. This means that not in every country BCG has been accepted as the 
first-line therapy for superficial tumors. 
In treating the adverse effects of BCG-treatment, options vary according 
to the severity of the toxicity from delaying or withholding instillations to 
treatment with antituberculous drugs for up to 6 months (Table 1). However, 
in general, 95% of the patients have no serious side effects. The recognition 
of risk factors, particularly traumatic catheterization or concurrent cystitis, 
that may result in systemic BCG absorption as well as the prompt and 
appropriate treatment of early side effects should significantly decrease the 
incidence of severe toxicity.24 
It is difficult to distinguish between therapy-related symptoms that may 
indicate efficacy of BCG and symptoms that may represent adverse effects. 
Many investigators believe that an inflammatory reaction is an important 
component of the response to BCG-therapy. In case of bladder-irritative 
symptoms, some investigators stop instillations because they consider this 
phenomenon a side effect while others continue the instillations presuming 
that by evoking inflammation, BCG is working optimally in that particular 
patient.25 Because the overall side effects of BCG-instillations are more 
pronounced than of chemotherapeutic drugs, attempts have been made to 
reduce the toxicity of BCG-therapy without affecting the efficacy of it. 
BCG is generally highly sensitive to antituberculous drugs of which Isoniazid, 
Rifampin, streptomycin and Ethambutol are well known. Of all antitubercu-
lous drugs Isoniazid is used most frequently. As these tuberculostatic agents 
are capable of curing patients with severe BCG-induced toxicity including 
16 
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BCG-sepsis, it might be that these agents, if used prophylactically can reduce 
side effects significantly. In an animal study, the administration of oral 
Isoniazid has shown to impair the immune response after intravesical BCG-
instillation.26 In humans, Isoniazid administration did not impair the local 
immune response after BCG-treatment.27 Because no data are available 
concerning the impact of Isoniazid on the antitumor efficacy of intravesical 
BCG in patients with superficial bladder tumors, the prophylactic use of 
antituberculous drugs is subject of investigation in several trials. 
A second method to reduce toxicity can be achieved by reducing the dose 
of BCG. However, also here the dilemma will be the same as for antituber-
culous drugs: Will the efficacy be maintained if toxicity decreases?28 
Table 1. Treatment recommendations for BCG-related complications. 
Fever less than 38.5°C No instillation 
Hold BCG until symptoms have resolved 
No instillation 
Isoniazid at 300 mg daily for 3 months 
May resume BCG when asymptomatic 
Isoniazid at 300 mg daily for 3 months 
Further BCG only if benefit exceeds risk 
Isoniazid at 300 mg. Rifampin at 600 mg 
Ethambutol at 1200 mg, daily for 6 months 
No further BCG 
BCG sepsis Isoniazid at 300 mg, Rifampin at 600 mg 
F.thambutol at 1200 mg daily for 6 months 
Consider Prednisolone at 40 mg 
intravenously and acutely 
THF. OPTIMAL DOSE 
Several studies are now ongoing to investigate the efficacy and toxicity of low 
dose BCG. A low dose (75 mg) of the Pasteur strain was compared to the 
standard dose (150 mg) by Pagano et al..28 The preliminary results indicate 
similar response rates in 87 patients. The recurrence-free rates were 90.5% 
(low dose) and 86.4% (standard dose) respectively. The incidence of local 
and systemic side effects, however, are significantly less in the low dose group. 
Cystitis was observed in 31% (low dose) and 54% (standard dose), while 
fever was noted in 14% and 26% respectively. Two dose-related studies have 
Fever greater than 38.5°C for 12-24 hours 
Allergic reactions 
Acute severe illness 
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been published in the USA. Morales et al.29 reported that a half dose (60 mg) 
of Armand Frappier BCG resulted in a reduction in overall efficacy: from 
67% success in 45 patients treated with 120 mg BCG to 39% in 41 patients 
treated with 60 mg BCG (p < 0.02). As BCG is a living preparation it is 
expected that storage of BCG will inevitable lead to reduction of the number 
of viable microorganisms. In a retrospective review performed by Blumen-
stein et al.,30 no evidence was found of reduced efficacy with reduced dose 
being estimated by the decline of colony forming units which occurs with 
shelf storage. The dose of most preparations is given by most manufacturers 
in milligrams and in colony forming units. It is advised to use per instillation: 
150 mg of Pasteur, Armand Frappier 120 mg, Connaught 120 mg and Tice 
50 mg. 
The number of colony forming units in one ampule varies between 
manufacturers and even between lots of the same substrain. The optimal dose 
at present ranges between about 3 χ IO8 and 1 χ IO9 colony forming units. 
The living bacteria are present as solitary bacilli but also as clumps containing 
5, 50 or even 500 bacilli. These clumps all grow in culture as if they developed 
from one solitary bacillus, ultimately forming one colony in the culture disk. 
In practice the number of colony forming units does not inform about the 
real number of bacilli present. It is also unknown whether a clump of bacilli 
acts differently compared to a solitary bacillus, with regard to immune 
stimulation when it adheres to the bladder wall. 
Regarding this information it is questionable whether a dose reduction of 
50% could have any impact at all. Probably a fourfold or more dose reduction 
should be investigated to address the item of dose reduction. 
IS INTRAVbSlCAL IMMUNOTHERAPY SUPERIOR 
TO INTRAVESICAL CHEMO THFRAPY' 
The question whether intravesical immunotherapy with BCG is superior to 
intravesical chemotherapy remains actual. There is no doubt about the 
efficacy of BCG in eradicating carcinoma in situ or preventing papillary 
tumors after transurethal resection. Although series are not large and follow-
up is too short, several reports indicate that BCG is capable to prevent muscle 
invasive disease.31 3 2 More data are needed to prove this observation. If the 
progression rate is lower, as assumed in low risk or intermediate risk tumors, 
the other important objective is to prevent recurrences. Recurrences are 
delayed using intravesical chemotherapeutics as well as BCG. However, BCG 
is more toxic and therefore the urologist has to make a risk to benefit analysis 
18 
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for the individual patient. Should he select a potent drug with pronounced 
adverse effects or a less potent drug with virtually no side effects? 
CONCLUSION 
Intravesical therapy with BCG has proven to be very effective in the prop-
hylaxis and treatment of superficial bladder tumors and carcinoma in situ. In 
most series, BCG is superior to intravesical chemotherapy in bladder cancer 
therapy. Because of the more pronounced side effects, the risk and benefit for 
the individual patient should be considered in individual patients. This means 
that for low- and intermediate-risk patients there seems to be a role for 
intravesical chemotherapy. 
BCG should not be administered to patients with low stage, low grade 
(stage pTa, grade I) unifocal or primary tumors. In patients with intermediate 
risk (50% of all patients) it is questionable, whether one should choose 
between effective chemotherapeutic drugs or BCG. In high risk patients 
(15%) BCG is therapy of first choice. In this category of patients the benefit 
of the therapy exceeds the risk of possible side effects and the disadvantage 
of long-term treatment. Certainly this is true for carcinoma in situ. 
A number of issues around BCG-therapy seems to have reached consensus 
now. An optimal route of administration has been defined as well as an 
optimal instillation scheme. Too few studies have been performed to reveal 
the best strain if there is any. Studies about the optimal dose are ongoing as 
well as studies to address the toxicity. It must be remembered, however, that 
BCG never will be the best treatment option for every patient with superficial 
bladder cancer. 
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INTRODUCTION 
Bacillus Calmette-Guérin (BCG) is an attenuated strain of Mycobacterium 
bovis commonly used for vaccination against tuberculosis. The use of BCG 
for immunotherapy of cancer has been extensively investigated, especially in 
the 1970s.1 
Laboratory studies have shown that BCG-administration can result in 
tumor regression and even tumor-specific immunity in several animal tumor 
systems. However, clinical use of BCG-immunotherapy in humans has been 
disappointed, except in superficial bladder cancer.2 Several independent 
clinical trials have proven that intravesical BCG-treatment is efficacious.3 
BCG reduces the recurrence rate after endoscopic surgery of papillary tumors. 
Moreover, BCG has become the drug of choice for the treatment of carcinoma 
in situ of the bladder urothehum and cures 60-70% of the patients.3 Impor-
tantly, intravesical BCG-treatment possibly may reduce progression of tumor 
grade and stage.4 
From the tumor-immunological point of view, immunotherapy seems 
indicated for transitional cell carcinoma of the bladder, since evidence exists 
that bladder cancer may be lmmunogenetic.5'6 
Depending on the route of administration, BCG is known to stimulate 
various parts of the immune system both at the humoral and at the cellular 
level. The cell-mediated immunity seems to be important for the activity of 
BCG as an immunotherapeutic agent against cancer.2'7 For treatment of 
superficial bladder carcinoma, BCG is repeatedly administered in the bladder 
cavity. 
This local application usually results in systemic immunity to BCG, which 
can be measured by a delayed type hypersentivity (DTH) reaction to purified 
protein derivate (PPD) in the skin.8 In the bladder wall of patients, mononu-
clear cell infiltrates with granunolomatous characteristics are induced after 
repeated BCG-administration. Recent immunohistochemical studies of these 
BCG-induced reactions have shown that the major infiltrating cell type is the 
T-lymphocyte. Macrophages and B-lymphocytes have been found in lower 
amounts. Induction of Major Histocompatibility Complex Class II (HLA-
DR) antigen expression on urothelial cells has also been reported.9 
The mechanisms by which BCG exerts its antitumor activity are not clearly 
understood.7 It may be that the induction of the PPD skin reaction and 
granulomatous bladder wall infiltrates are associated with the clinical res-
ponse of patients.8,10 In animal models, T-lymphocytes also seem to play a 
crucial role in the mode of action of BCG.111-
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To gain inside in the antitumor activity of BCG, the histopathological 
reactions induced by intravesical BCG-administration in the guinea pig model 
have been studied.13 
To evaluate immunological reactions in patients with superficial bladder 
cancer treated with BCG the immunological products in the urine of these 
patients were analysed. This is a non-invasive alternative for the study of 
immunological reactions in comparison with histopathological studies. The 
desquamated leucocytes from the bladder wall present in spontaneously 
voided urine of patients after BCG-treatment have been studied. Also the 
presence of the cytokines: Interleukmel (ILI), Interleukine2 (IL2), Interleu-
кіпеб (IL6) and Tumor Necrosis Factor α (TNFa), which are products of 
leucocytes present in the bladder wall, was investigated in the urine of these 
patients. 
MATERIALS AND METHODS 
Patients with superficial bladder cancer were treated with weekly instillations 
for 6 consecutive weeks. BCG (RIVM-strain) was used in a dose of 5xl0 8 
colony forming units per instillation. 
Leukocytes from urine 
Voided urine was collected before (T0) and approximately 24 h (T,4) and 48 
h (T48) after BCG-instillation number 1 (2 patients) and after 5 and more 
instillations (8 patients). The mean percentages of viable cells was determined 
by trypan blue (0.5%) exclusion. 
Immunofluorescence staining 
For fluorescence-activated cell sorter (FACS) analysis, cells (5xl05) were 
labelled with the following monoclonal antibodies: FK32 (anti-CD15, gra­
nulocytes), anti-HLel (anti-CD45, leucocytes); anti-Leu-M3 (anti-CD14, 
monocytes/macrophages); anti-Leu-12 (anti-CD19, B-lymphocytes); anti-
Leu-4 (anti-CD3, T-lymphocytes); anti-Leu-2(anti-CD4,helper/inducer T-
lymphocytes); anti-Leu-3 (anti-CD, helper/inducer-lymphocytes); anti-Leu-2 
(anti-CD8, suppressor/ cytotoxic T-lymphocytes); anti-Leu-llc (anti-CD16, 
NK-cells); anti-Leu-19 (anti-CD56, NK-cells); anti-IL2-R (anti-CD25, IL-
2receptor); anti-HLA-DR (la nonpolymorphic). 
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Flow cytofluorometry and analysis 
Twelve thousand cells were measured with a FACScan (Becton Dickinson 
Immunocytometry Systems, Mountain View, CA,USA) and analysis of the 
data was performed with FACScan software on a Packard 9920S computer. 
Lymphocyte subpopulations were determined with a selective cell meas-
urement procedure.15 
Detection of ILI, IL2, IL6 and TNFa 
Determination of ILI, IL2, IL6, T N F a and IFN7 in urine specimens was 
performed in urines collected before instillation and 2, 4, 6, 8 and 24 hours 
thereafter, during 6 weekly instillations. Urine was immediately frozen to 
-20°C. Afterwards it was thawed, centnfuged, dialysed and sterilized. The-
reafter samples were stored (-20°C) until determination of cytokines. 
ILI was measured with the T-cell line D10(N4)M. The nature of the ILI 
in some urine samples was investigated by neutralization tests. For detection 
of IL2 a specific bioassay with the IL2-dependent murine T-cell line CTLL-16 
was used. IL6 was measured with the hybndoma growth factor assay B9. 
TNFa was determined with a T N F a specific ELISA. IFN7 was measured with 
a commercially available ELISA (Holland Biotechnology, Leiden, The 
Netherlands). The detection limits of the various assays were 6 U ILI, 0.5 U 
IL2, 2 U IL6, 50 pg T N F a and 1 U IFN7 per ml urine. The results were 
standardized to urine creatinine (U/pmol or pg/mmol creatinine) so that 
sample data were comparable, regardless of the urine volume. The mean 
creatinine concentration for all samples was 7.6 ± 3.9 pmol/ml urine (n=195). 
RESULTS 
Leucocytes in the urine 
The presence of leucocytes in the urine was studied in 7 patients with 
superficial bladder cancer who were treated with BCG. 
The total number of cells in urine was markedly increased at 24h and 48h 
after five or more BCG-instillations (Figure 1), indicating a local cellular 
reaction of the immune system induced by BCG. At all times investigated, the 
majority of the cells were granulocytes (CD15+); however, monocytes/ma-
crophages (CD14+) and T-cells (CD3+) were also clearly detectable. B-cells 
(CD19+) were scarcely present (Table 1). 
The lymphocyte subpopulations determined in the urine, based on analysis 
of cells in the lymphocyte gate,15 after five or more BCG-instillations are 
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Figure 1. Increase in the total number of cells and in leucocyte subpopulations in urine of 7 
patients after five and more BCG-instillations, p<0.02 Wilcoxon matched-pairs signed-rank 
test. 
Table 1. Percentages of cells in leucocyte subpopulations in urine after repeated intravesical 
BCG-instillations. 
Cell type 
Granulocytes'' 
Monocytes/macrophagesb 
T-lymphocytes' 
B-lymphocytes'1 
Cell composition (%) after 
CD 15* 
С О Н ' 
CD3+ 
CD 19+ 
0 
61 ± 20' 
(7) 
5 ± 6 
(7) 
4 ± 6 
(5) 
24h 
75 ± 11 
(8) 
4 ± 2 
(8) 
1 ± 1 
(5) 
48h 
6 2 * 14 
(7) 
4 ± 4 
(7) 
1 ± 1 
1 ± 1 
J 5 ] _ 
0 ± 0 
(5) 
0 ± 0 
(5) 
* Time before (t=0) or after the fifth or more BCG-insnllation. 
ь
 Determined by flow-cytofluorometric analysis of the total cell population with FSC 200. 
' Percentage of total number of cells; mean ± s.d. of (n) patients. 
J
 Determined by flow-cytofluorometric analysis of the cells in the lymphocyte gate. 
presented in Table 2. For 3 patients the lymphocytes could not be analyzed 
in pretreatment specimen due to the lower number of cells. The mean 
percentage of the cells within the lymphocyte-gate reacting with the anti-
CD45 mAb was 78 ± 25%, 75 ± 17% and 74 ± 7% at TQ, T,4 and T 4 8 
respectively. 
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Table 2. Subsets of lymphocytes3 present in urine after repeated BCG-instillations. 
cell type 
T-cells 
T-helper/inducer 
T-suppressor/cytc 
IL-2 receptor 
HLA-DR 
NK-cells 
B-cells 
Monocytes/macrc 
Granulocytes 
CD4/CD8-ratio 
>toxic 
^phages 
CD cluster 
CD3* 
CD4* 
CD8' 
CD25' 
CD16*CD56* 
CD 19' 
CD14* 
CD15* 
Cell compositionb (%) aftei 
0 
86 ± 2 1 
(5) 
62 ± 9 
(3) 
19 = 5 
(3) 
3 ± 3 
(4) 
44 ± 2 0 
(5) 
1 0 ± 7 
(5) 
19 ± 2 8 
(5) 
4 ± 6 
(5) 
9 ± 4 
(5) 
3.6±1.2 
(3) 
24h 
73 ±12 
(8) 
53 ± 9 
(8) 
23 ± 6 
(8) 
19 * 11** 
(8) 
4 7 ± 1 8 
(7) 
1 6 ± 7 
(8) 
13 * 17 
(8) 
4 ± 2 
(8) 
7 ± 6 
(8) 
2.4±0.7 
(8) 
r
l
' 
48h 
77 ± 13 
(5) 
49 ± 6 * 
(5) 
19 ± 9 
(5) 
10 ± 4* 
(5) 
62 ±25 
(5) 
15 ± 11 
(5) 
24 ±26 
(5) 
4 ± 2 
(5) 
16 ± 8 
(5) 
3.0± 1.1 
(5) 
* Flow cytofluorometric analysis of cells in the lymphocyte-gate after selective cell measure­
ment. 
ь
 Positive cells expressed as percentage of the CD45* cells (mean ± s.d. of η patients). Per­
centages CD45* cells were 78 ± 25 % (n=5), t=0; 75 ± 17 % (n=8), t=24; 74 ± 7 %, 
(n=5),t=48. Percentages of positive cells were determined by substracción of a conjugate 
control (HLA-DR and FK32) or isotype-control (others). 
1
 Time before (t=o) and after the fifth or more BCG-instillation. 
* ρ 0.05 (student's t-test) 
** ρ 0.02 (student's t-test) 
Since with the anti-CD45 Mab all types of leucocytes are detected, the number 
of cells reacting with the other Mabs used were expressed as percentage of 
the CD45+ cells (Table 2). The major lymphocytes were mostly of the CD4* 
(helper/inducer) phenotype. 
At the T 4 g the mean percentage of CD4
+
 cells was significantly lower than 
in pre-instillation samples (49 ± 6% vs 62 ± 9% respectively). 
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Figure 2. Cytokine levels in urine during six consecutive BCG-instillations once a week. Data 
presented are, for individual patients, the cytokine concentrations determined pre-trcatment, 
i.e. before the first BCG-instillation (pre) and the highest cytokine concentration measured per 
instillation. · cytokine concentration in urine of 7 individual patients (pre, 4 patients), 
mean. — minimal detection limit. 
In all urine specimens investigated, the percentages of CD8+-cells was lower 
than the percentage of CD4+-cells (CD8+ 19-23% and CD4+ 49-62%). The 
CD4/CD8-ratio showed a tendency to be decreased after 24h, when compa­
red to pre-instillation values (2.4 ± 0.7 vs 3.6 ±1.2 respectively). 
HLA-DR expression was observed in a considerable percentage of the 
lymphocytes (44-62%) at all time points (Table 2). The percentage of 
lymphocytes with expression of the IL2-receptor (CD25) was significantly 
increased both 24h and 48h after instillation of BCG (19 ± 11% at T, 4 and 
10 ± 4% at T 4 8 vs 3 ± 3 % at TQ, ρ з= 0.05 and ρ =s 0.05 and ρ < 0.02 
respectively). The mean percentage of NK-cells (CD16+ and/or CD56+) was 
10-16%. However, since granulocytes may also express the CD16 antigen 
(Fc receptor), the real percentage of NK-cells may be lower. CD16+ and/or 
CD56+ were generally CD3. The percentage of B-cells (CD19+) was 13-24%. 
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As is shown in Figure 1, the total number of cells was markedly increased 
after five or more BCG-instillations. Thus the absolute numbers of all the 
lymphocytes subsets, as shown in Table 2 , were increased after BCG-instil-
lation. 
Cytokines in the urine 
To study cytokines in the urine of BCG treated patients, urine collected from 
7 patients could be analysed. In Figure 2 the concentrations of the cytokines 
ILI, IL2, IL6, TNFa and IFN7 in the urine collected before (pre-treatment) 
and during a 6-week treatment course for individual patients are shown. In 
generally the cytokine concentrations in the pre-treatment samples were low 
or zero, only for ILI and IL6 occasionally considerable levels were detected. 
During treatment the highest concentration for each instillation number 
measured during the first 24h after the instillation is presented. 
During the first three BCG-instillations the concentration of ILI increased 
markedly, reaching a plateau after 3 instillations. IL2 was not detected after 
the first BCG-instillation, but for the second instillation and onwards the 
mean IL2 concentration increased rapidly. With respect to IL6, patients 
already had relatively high levels in the urine after the first BCG-instillation. 
A moderate increase of the IL6 concentration was observed during the 
consecutive weeks. 
Like IL2, TNFa was only detected after repeated BCG-instillations. The 
total number of samples positive for TNFa was low. In the urine of all of the 
7 patients investigated, positive concentrations of ILI, IL2 and IL6 were 
measured at least once during the 6 weeks. However, for urinary TNFa 2 of 
the 7 patients remained negative during the complete 6-week instillation 
course. IFN7 could not be demonstrated. The mean concentrations of ILI, 
IL2, IL6 and TNFa in urine collected at regular time intervals during the first 
24h after the BCG-instillations are presented in Figure 3. For this data, urine 
samples after the instillations 4 to 6 are used. TNFa, IL2 and IL6 were clearly 
detecTable by 2 hours after the instillation. In contrast, ILI seemed to occur 
later, i.e. from 4 hours onwards. TNFa decreased most rapidly; it was nearly 
absent in 6 hour samples. Generally, IL2 was no longer detectable in the 8 
hour samples, whereas ILI and IL6 were presented up to 8 hours after 
instillation of BCG. The bioassay used to measure ILI did not discriminate 
between ILla and ILI β. In neutralization experiments with anti-ILla and 
anti-ILlß antibodies, we observed that inhibition of the biological ILI activity 
in the urine was mainly exerted by the anti-ILla Mab, which indicates that 
most of the ILI induced by the BCG-treatment is ILla. (Figure 4) 
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Figure 3. Occurrence of cytokine peak levels in urine during the first 24 hours after BCG-in-
stillation 4-6. Peak level = highest cytokine concentration of the 24 hours after an instillation, 
evaluated per patient. Frequency of peak levels expressed as percentage of the number of 
samples of all patients investigated at each time point. 
Additionally, cytokine concentrations were determined in urine of 2 patients 
intravesically treated with Mitomycin-C, a chemotherapeutic agent. Non of 
these specimens, obtained before and at several time points after the 6th 
Mitomycin-C-instillation, were positive for any of the cytokines. 
DISCUSSION 
The presence of leucocytes and cytokines in urine of BCG-treated patients 
with superficial bladder cancer indicates immunological stimulation by intra­
vesical BCG. T-lymphocytes seem to play a crucial role in the antitumor 
activity of BCG.11,12 The main cell type reported to be induced by BCG in the 
bladder wall of patients is the T-lymphocyte.9 The major type of lymphocytes 
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Figure 4. Neutralization of ILI activity present in urine after intravesical BCG-treatment. 
found in urine specimens were also T-cells (CD3+). The majority of T-cells 
were CD4+ (helper/inducer), whereas CD8+ (suppressor/cytotoxic) T-
lymphocytes were less present. The high CD4/CD8-ratios calculated and the 
relatively low numbers of NK-cells and B-lymphocytes (Table 2) are in 
agreements with the observations in biopsies and bladder washings after 
BCG-administration.9,16 This suggests that the lymphocytes in urine may be 
a representation of the lymphocytes in the bladder wall after local admini­
stration of BCG. Expression of HLA-DR and IL2-receptors indicate activa­
tion of the T-lymphocytes by intravesical BCG-treatment. 
Interleukin-2 is known to be produced by T-lymphocytes.17 The presence 
of T-cells only after repeated BCG-instillations is possibly related to the 
presence of 1L2 which was also observed only after repeated BCG-instilla­
tions. 
These observations may indicate the induction of a T-cell mediated 
immune reaction. IFN-y is also a product of activated T-cells.18 IFN7 is 
unstable in urine,19 which may be the reason that we did not detect this 
cytokine. 
Monocytes / macrophages are generally considered as potential producers 
^5 
of ILI, IL6 and TNFa.20,2122 The ILI, IL6 and TNFa in the urine may be 
produced by macrophages, as these cells can be directly stimulated by BCG 
or mycobacterial antigens resulting in the release of these cytokines.23'24,25 
The fact that the type of ILI found in the urine after BCG-treatment was 
mainly ILla, is in agreement with our in vitro studies on ILI production by 
human monocytes (L.A. Aarden, unpublished data). To date, the release of 
ILI, IL6 and TNFa has been reported for a number of other different cell 
types, like T-cells, endothelial cells, fibroblasts, epithelial cells or poly-
morphonuclear granulocytes.20·21·22 This means that at least partly production 
by other cell types cannot be excluded. 
Our data on the time of presence of the cytokines are generally comparable 
to results of other studies.26'27'29 The increase of the concentration of all 
cytokines, which was found during the 6-week instillation course, may reflect 
an increase in the number of leucocytes infiltrating the bladder wall. For 
monitoring purposes, we suggest collection of urine during the first 6h after 
BCG-instillations four to six, since at these times the highest concentrations 
of important cytokines were observed. 
The rationale of the BCG-treatment is to activate the immune system, ending 
up in an immunological reaction against locally present bladder tumors cells 
and tumor cell degradation.7 Our investigations indicate a local recruitment 
of leucocytes which are potentially cytotoxic to tumor cells, like cytotoxic 
T-cells, NK-cells, monocytes/macrophages and granulocytes.30'31'32,33 
The induced cytokines may play a role in activation of these leucocytes. 
17,20,21,22,24 Besides immunomodulating properties, the cytokines themselves 
may have direct cytotoxic/cytostatic effects on tumor cells.35'36,3738 As the 
actual effector mechanism of BCG against superficial bladder cancer has not 
yet been elucidated, functional investigation of these leucocytes is warranted. 
Furthermore, the presence or absence of cytokines may correlate with the 
individual prognosis of the patients with superficial bladder cancer.39 
CONCLUSION 
The clear increase in the number of granulocytes, monocytes/macropges and 
T-lymphocytes which were observed in the urine 24 hours after BCG-instil-
lations, indicate local activation of the immune system. The antigen expres-
sion of the lymphocytes suggested that they may represent the lymphocytes 
in the bladder wall. 
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These leukocytes may be usefull for functional studies, which are essential to 
elucidate the actual effector mechanism(s) in the mode of action of BCG 
against superficial bladder cancer in man. 
The detection in the collected urine samples of IL2 are considered as the 
results of activation of BCG-specific T-cells. The presence of ILI, IL6 and 
TNFa might suggest activation of macrophages. 
The combination of the observed leucocytes and cytokines may play an 
important role in the antitumor activity of BCG against bladder cancer. The 
presence or absence of cytokines may also have prognostic value concerning 
the clinical response on BCG-therapy. 
The analysis of immunological products in the urine of superficial bladder 
cancer patients after intravesical immunotherapy with bacillus Calmette-
Guérin contribute to understand the actual effects of the antitumor activity 
of BCG. 
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INTRODUCTION TO CHAPTER 4 
The primary goal of intravesical chemotherapy in patients with bladder 
cancer is to eradicate the existing disease (treatment) and/or to prevent 
recurrent disease (prophylaxis). Superficial bladder cancer, initially treated 
with transurethral resection has a tendency to recur and to progress and 
therefore intravesical prophylaxis of recurrence is essential. A minority of the 
patients with recurrent superficial bladder disease will eventually progress 
and the question remains whether intravesical chemo-immunotherapy can 
influence or, if possible, eventually prevent progression. It is obvious that 
dealing with carcinoma in situ, a superficial bladder cancer not amendable 
by transurethral resection, intravesical therapy has a therapeutic objective, 
which can be evaluated by cytology. 
Differences in therapeutic efficacy and toxicity of intravesical therapy with 
immunological agents can be evaluated in prospective randomized trials. 
Clinical prospective research is indeed essential to underline advantages and 
disadvantages of one substance over another. Moreover, it is essential to 
compare the efficacy and value of intravesical immunotherapy with intrave-
sical chemotherapy. For this reason the Dutch South-East Cooperative Uro-
logical Group has executed different trials, comparing intravesical immuno-
therapy and chemotherapy, and this chapter deals with a large randomized 
trial comparing intravesical Mitomycin-C therapy with BCG-Tice and BCG-
RIVM in the treatment of pTa-pTl papillary carcinoma and carcinoma in 
situ of the urinary bladder. 
This trail started in 1987 and was closed for inclusion as of 1991. The first 
results of this trial with respect to toxicity, local and systemic side-effects has 
been reported in 1993 by Witjes et al..1 This publication also described a 
preliminary (lack of) difference between the three treatment arms. 
Maturity of the data and results of a clinical trial are usually obtained when 
at least 50% of the patients have shown a recurrent tumor. After two years 
of followup, as published by Witjes et al , the recurrence rate in the Mitomy-
cin group was 35%, in the BCG-Tice group it was 46% and in the BCG-
RIMV group it was 38% respectively. An updated evaluation in 1995, as 
described in this paper, did not completely reach the maturity as defined 
above, but the recurrence rates were still less than 50%, namely 43% in 
Mitomycin-C, treated patients, 64%in the BCG-Tice group and 46% in the 
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BCG-RIMV group. However, these percentages show that close to 50% of 
the patients had experienced a recurrence. 
It is remarkable that the increase in recurrence rate between 2 and 5 years is 
only small and limited and hence it is difficult to estimate when exactly the 
50% recurrence rate in all three arms will be reached. This is (partially) due 
to the selection criteria used in the trail, which also included patients with 
low risk of recurrence. This is one of the flaws of this trail as described in the 
discussion of chapter 4. 
The progression rate in patients with superficial bladder cancer is low. A 
former study analyzing the available clinical outcome data within the Dutch 
South-East Cooperative Urological Group (Kiemeney et al.2) have calculated 
the actual risk of disease progression for primary superficial bladder cancer 
into at least pT2 tumors as 10.2% after 2 years with hardly any increase after 
5 years till 13.3%. This is somewhat lower than progression rates usually 
described in literature (+/- 20%) but the latter is an estimation rather than a 
fact. 
It also depends on the initial stage (pTa or pTl) and grade (grade 1 to 3 
+/- carcinoma in situ) of the tumors described in the different series. In view 
of the low recurrence rate, it is difficult to estimate or calculate the influence 
of intravesical therapy on progression. However, this is an important fact 
since the value of intravesical therapy would increase tremendously when it 
could be proven that it influences progression. So far this has not been 
observed in the study described in chapter 4 and has not been described in 
other randomized trails except for an anticipating calculation as described by 
Lamm et al..3 However, the assumption of Lamm is a statistical consideration 
rather than an outcome of a clinical trial. To evaluate the influence on 
progression of intravesical therapy, another study design is needed with 
higher numbers of patients having tumors with a higher risk of recurrence 
and progression and with a (very) long followup. This has not been the case 
in any of the studies published so far and it is also not possible to analyze this 
in the study described hereafter. However, the value of the described study 
is, that it did analyze in detail the effect on superficial bladder recurrence 
which is an objective trial endpoint and can be considered as treatment failure. 
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ABSTRACT 
Results of a randomized prospective study are reported in which Mitomycin-
C, Bacillus Calmette-Guérin (BCG)-Tice strain and BCG-RIVM strain are 
compared in 437 patients with primary or recurrent pTa and pTl bladder 
tumors, including carcinoma in situ. The followup (= time in study) varied 
from 2 till 81 months (mean 36 months). After complete transurethral 
resection of all visible tumors the patients have been treated with Mitomy-
cin-C (30 mg once a week for 4 consecutive weeks and thereafter every month 
for a total of 6 months), BCG-Tice or BCG-RIVM (5 χ IO8 colony forming 
units once a week for 6 consecutive weeks). 
For papillary tumors the Mitomycin-C and BCG-RIVM treatments were 
equally effective (p=0.53). Mitomycin-C was more effective than BCG-Tice 
therapy (p=0.01). 
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INTRODUCTION 
In pTa and pTl bladder cancer both intravesical chemotherapy and immuno-
therapy are used as adjuvant treatment after transurethral resection. Both 
therapies can reduce the high rate of recurrences in papillary tumors as well 
as eradicate carcinoma in situ.1 '2 ' '4 '5 Response rates of different studies 
comparing chemotherapeutical agents versus BCG after transurethal resec-
tion in patients with pTa, pT l and carcinoma in situ bladder tumors suggests 
that BCG is superior to Thiotepa, Doxorubicin or Mitomycin-C.4 '6 
Mitomycin-C was selected as a chemotherapeutic agent in this study 
because of its proved efficacy in regard to prevention of tumor recurrence 
and high response rate in patients with carcinoma in situ.7'8'9 
In 1988 we reported the results of a prospective trial in which Mitomy-
cin-C was compared with BCG-RIVM, and no statistically significant diffe-
rences in toxicity and efficacy were noted between the two arms.10 Because 
of the lack of superiority of BCG-RIVM over Mitomycin-C, the efficacy of 
BCG-RIVM was questioned. BCG is a biological product, consisting of living 
bacteria, subcellular debris and adjuvant compounds. Considerable differen-
ces in the various strains and even in lots of the same strain can be present." 
Most of the BCG-strains, e.g. BCG-Tice, are grown as a surface pellicle, 
ground in a ball mill, resuspended and freeze dried. BCG-RIVM, however, is 
grown in a homogeneously dispersed culture and lyophilized in a solution 
containing glucose and tween 80. 
It has been suggested that those strains with the best ability to bind to 
fibronectin could be the strains with the most potent antitumor efficacy. The 
glycoprotein fibronectin has an important role in the attachment of BCG to 
the bladder wall, which has been demonstrated in mice.12 At least in the 
mouse model BCG-strains grown as a surface culture (Tice) showed a better 
attachment to the bladder wall than homogeneously dispersed cultured BCG 
(RIVM). n 
These observations led to the necessity to compare the two different 
BCG-strains to each other and to a well known chemotherapeutic drug. 
Objectives of the study 
The first objective of this three-arm prospective, controlled and randomized 
trial was to compare the efficacy of Mitomycin-C chemotherapy with that of 
BCG-immunotherapy, using two different substrains in patients with primary 
or recurrent pTa, pT1 and carcinoma in situ bladder tumors. The parameters 
compared were duration of disease-free interval and the rate of progression 
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to a higher stage (T category) of disease. 
The second objective was to compare the incidence and seventy of side 
effects of the treatments. 
Primary endpoint of the study was the time to recurrence of bladder 
tumors, which was considered treatment failure. 
MATERIALS AND METHODS 
From april 1987 to december 1990, 469 patients entered the study from 27 
institutions of the Dutch South East Cooperative Urological Group. All 
patients had histologically proved papillary pTa-pTl transitional cell carci­
noma of the bladder with or without concomitant or primary carcinoma in 
situ. Pathological classification was done according to the T N M system,1 4 
and grading of the tumors was done according to the method of Koss.'5 The 
highest stage and grade of all tumor specimens in individual patients were 
used to characterize each patient. All specimens of tumor and bladder biopsies 
were reviewed by a single pathologist. 
The toxicity, local and systemic side effects, has been reported elsewhere.1 6 
Briefly, side effects were divided as local, systemic or allergic. Local toxicity 
was defined as the occurrence of culture proved bacterial cystitis (not BCG 
related), drug-induced cystitis (Mitomycin-C or BCG related) or other local 
side effects, such as hematuria, prostatitis and epididymitis. The seventy of 
side effects was scored by classifying them as requiring no delay, delay or 
cessation of instillation therapy. 
Treatment 
Intravesical chemotherapy consisted of 30 mg Mitomycin-C in 50 ml saline 
instilled once a week for 1 month (week 1 to 4) and thereafter once a month 
for a total of 6 months. If superficial tumor recurred or carcinoma in situ 
persisted at 3 months the treatment schedule was not changed after complete 
transurethal resection (or biopsy) and if disease recurred or persisted after 6 
months 3 additional monthly Mitomycin-C instillations were given. 
Intravesical immunotherapy was performed with BCG-Tice or with BCG-
RIVM. BCG was administered (5 χ IO8 colony forming units in 50 ml saline) 
once a week for 6 consecutive weeks. If superficial tumor recurred or 
carcinoma in situ persisted at 3 or 6 months a second 6-week course with 
BCG-instillations was given after complete transurethral resection or biopsy. 
In all other cases of recurrences, irrespective of the treatment arm, the patient 
went off study and treatment was left to the discretion of the urologist. 
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Followup and treatment response 
Followup cystoscopy was performed at 3-month intervals during the first 2 
years after transurethal resection, and thereafter at 4 and 6-month intervals. 
Cytology was done at each cystoscopy. 
For papillary tumors the efficacy of the therapy was evaluated by deter-
mining the disease-free period after randomisation. 
The response to therapy in patients with carcinoma in situ was scored as 
no response or a complete response. Complete response was defined as the 
complete disappearance of carcinoma in situ, documented by normal urine 
cytology, cystoscopic examination and bladder biopsies. 
Statistical analysis 
To detect a difference of 50% in the median duration of the disease-free 
interval between Mitomycin-C and the best (smallest hazard rate) of the 
BCG-treatments (assuming the time to recurrence follows an exponential 
distribution), 90 eligible and évaluable patients followed until recurrence 
were required in each treatment arm (error probabilities α = 0.05 and β = 
0.20). Assuming that 65% of the patients will have at least one recurrence 
during the study, 138 évaluable patients per treatment arm were needed, for 
a total of 414 évaluable patients. For randomization the restricted blockwise 
(blocksize 6 equals 3 treatments times 2 patients per treatment) randomisa-
tion was used. Estimation of the cumulative distribution of the disease-free 
interval was performed by the Kaplan-Meier method for each of the three 
treatment groups and for subgroups. Differences in the distribution of the 
disease-free interval were tested with the log rank test. For testing of the 
difference between sample percentages the chi-square test was used. All 
statistical computations were done using Statistical Analysis System proce-
dures 
RESULTS 
Eligibility 
Of the 469 patients who entered the study, 17 patients (6%) were ineligible 
because of no malignancy after pathological review (n=9), tumor stage greater 
than pTl after pathological review (n=6) and prior intravesical chemotherapy 
(n=2), and they were excluded from subsequent analysis. Another 15 patients 
(3%) were also excluded from subsequent analysis because of first instillation 
more than 4 weeks after transurethal resection (n=4), no instillations started 
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due to hematuria (n=2), refusal (n=2), medication problems (n=2), death 
(n=l), myocardial infarction (n=l) before the instillation procedure and other 
reasons (n=3). Ultimately 437 patients were eligible for analysis. Followup 
(time in study) of these patients varied from 2 to 81 months (mean 36 
months). 
Patient and tumor characteristics 
Tumor characteristics were equally distributed among the 3 treatment arms 
(Table 1 ). Of the 437 eligible patients, 50 had carcinoma in situ, 254 had pTa 
tumors and 133 patients had pTl tumors (Table 1). Of the patients with 
carcinoma in situ, 12 received Mitomycin-C, 23 received BCG-Tice and 15 
BCG-RIVM. After complete transurethral resection patients with pTa or pTl 
papillary tumors were treated with Mitomycin-C (136), Tice-BCG (117) and 
RIVM-BCG (134). Of the patients with carcinoma in situ 25 patients had 
pure flat multifocal carcinoma in situ and 25 also had papillary tumors 
(concomitant carcinoma in situ). Of all patients 84 had pTaGl tumors, 
including 43 patients with a solitary tumor and 41 patients with multiple 
(2-8) tumors. 
Off-study patients 
A total of 230 patients (74 Mitomycin-C, 76 BCG-Tice, 80 BCG-RIVM) went 
off study because of recurrence at or after 9 months (122), protocol violation 
(36), progression in tumor stage to T2 or higher (23), adverse effects (14), 
intercurrent death (10), treatment refusal (7), lost to followup (3) and other 
reasons (15). A detailed differentiation of reasons for off study is shown in 
Table 2. 
Efficacy of treatment 
For stages pTa andpTl papillary tumors the time to first recurrence was recorded. 
Recurrence was noted during the study in 58 of 136 patients (43%) treated with 
Mitomycin-C, 75 of 117 (64%) treated with Tice-BCG and 62 of 134 (46%) 
treated with RIVM-BCG. The estimated percentages of disease-free patients in 
the 3 treatment arms are shown in Table 3 The analysis of efficacy in the 
patients with papillary tumors shows a statistically significant difference 
among the treatment arms (p=0.04). The Mitomycin-C and BCG-RIVM 
treatments were equally effective (p=0.53), but Mitomycin-C treatment was 
more effective than BCG-Tice (p=0 01), see Figure 1. 
For carcinoma in situ tumors the complete response was analyzed as 
parameter of efficacy. In all patients with carcinoma in situ the complete 
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Table 1. Tumor characteristics of évaluable patients and allocation to treatment. 
Gl 
p T a G 2 
G3 
Gl 
p T l G 2 
G3 
primary 
recurrent 
total pap.tumors 
carcinoma in situ 
Mitomycin-C 
(148) 
24 
55 
4 
_ 
31 
22 
104 
32 
136 
12 
BCG-Tice 
(140) 
28 
48 
5 
_ 
18 
18 
87 
30 
117 
23 
BCG-RIVM 
(149) 
32 
54 
4 
_ 
23 
21 
108 
26 
134 
15 
Total 
(437) 
84 
157 
13 
254 (65.6%) 
_ 
72 
61 
133 (34.4%) 
299 
88 
387 
50 
Table 2. Reasons off study differentiated by treatment arm. 
Recurrences 
Protocol violation 
Progression 
Adverse effect 
Death 
Refusal 
Lost to followup 
Other 
TOTALS 
Mitomycin-C 
no-cis" 
31 
14 
65 
BCG-Tice BCG-RIVM Total 
cis""r no-cis'1' cis'*" no-cis* cis*"f no-cis* CIS* 
39 36 106 
28 
16 
5 
5 
2 
62 
2 
2 
2 
-
-
-
14 
4 
4 
4 
5 
1 
6 
66 
4 
-
1 
-
-
2 
14 
17 
12 
7 
7 
3 
13 
193 
6 
2 
3 
-
-
2 
37 
no carcinoma in siru; carcinoma in situ 
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response was 68% for a duration of 2 till 49 months (mean 19). Complete 
response was 67% (8 of 12 patients) for Mitomycin-C, 74% (17 of 23) for 
Tice BCG and 60% (9 of 15) for RIVM-BCG. These results do not allow any 
conclusion to be drawn because the numbers of patients randomized are too 
small. 
Table 3. Treatment efficacy, defined as percentage of patients free of tumor at 5 years of 
followup. % disease-free with standard error, all papillary tumors. 
1 year 
2 years 
3 years 
4 years 
5 years 
M tomycin 
73±4 
61-5 
59*5 
57±5 
57±5 
С BCG-Tice 
66±5 
53*5 
42±5 
36*5 
36-5 
BCG-R1VM 
70-4 
61-5 
55±5 
54-5 
54-5" 
* no failures seen after 4 years 
a s e - f - t e эт« ano D T I tumours 
О 9 
о а 
О 7 
О Б 
О 3 
О 3 -
0 0 0 5 1 0 1 5 2 0 2 5 3 0 3 5 4 0 4 5 D O 5 5 
t i m e i n y e a r s 
ТЙмТ TICE Itm) BCG - - - - BCG-ЙІ м M i t o m y c i n С 
Figure Í. Kaplan-Meier plots of the percentage of patients with papillary tumors pTa and pTl, 
grade 1 -3 transitional cell cancer, free of tumor after transurethal resection and treatment with 
Mitomycin-C (dashed line), BCG-Tice (solid line) and BCG-RIVM (dotted line). Log-rank test: 
p=0.04. 
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Progression in tumor stage 
Progression in stage (pT2 or higher) at recurrence (patients who went off 
study) was observed in 8 (6%) patients of the Mitomycin-C-group, 7 (5%) 
of the BCG-Tice group and in 8 (6%) treated with the BCG-RIVM. 
Toxicity 
The number and severity of adverse effects were recorded during the instilla-
tion period (6 months for Mitomycin-C, 6 weeks for BCG) and are listed in 
Table 4. Between the BCG groups no statistical difference in number and 
severity was found. Drug-induced cystitis, other local side effects and systemic 
side effects were significantly less frequent in the Mitomycin-C group. Three 
of 148 patients (2%) had to stop Mitomycin-C treatment, 5 of 140 (4%) 
stopped Tice BCG and 11 of 149 (7%) stopped RIVM-BCG. No life 
threatening adverse effects or treatment related deaths were recorded. 
DISCUSSION 
The primary objective in this study was to compare the efficacy of Mitomy-
cin-C chemotherapy with that of BCG-immunotherapy, using 2 different 
strains, in patients with pTa, pTl and carcinoma in situ bladder cancer. The 
efficacy in patients with papillary tumors was related to the percentage 
disease-free period after transurethal resection of all visible tumors. When all 
patients with papillary tumors (grades 1, 2 and 3 and stages pTa and pTl) 
were analyzed together a statistical significant difference was seen in efficacy 
among the 3 treatment schemes in favor of the Mitomycin-C and BCG-RIVM 
treated patients when compared to BCG-Tice treated patients. 
Because of statistical reasons, definitive results of this study should be 
withheld until at least 50% of patients in each of the 3 arms have shown 
recurrent tumor. However, after 3 years of followup only the BCG-Tice group 
has a slight decrease from 42% disease-free at 3 years to 36% after 4 and 5 
years, respectively (Table 2). The disease-free percentage for Mitomycin-C 
decreases only from 59% at 3 years to 57% at 5 years and for BCG-RIVM 
it decreases only from 55% to 54% at 3 and 5 years, respectively. Since in 
superficial bladder studies most recurrences are observed in the first 2 years 
after randomization, it is hard to estimate how many years are needed to 
obtain less than 50% disease-free in all 3 arms (see fig.). 
Only a few studies have presented a 5 year followup of patients with 
superficial bladder cancer treated with Mitomycin-C or BCG. Lamm17 repor-
ted the estimated 5-years recurrence rates of 78% for Mitomycin-C treated 
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Table 4 Side effects during instillation period 
bacterial cystitis (p= 
no 
yes, without delay 
yes4, with delay 
stop treatment 
Ю20) 
Mitomycin-C 
121 
25 
1 
1 
total yes (%) (18 2 ) 2 7 
drug induced cystitis (p=0 009) 
no 
yes, without delay 
ves, with delay 
stop treatmtnt 
- - -
total yes (%) 
allergic reaction (p=0 30) 
no 
yes, without dchy 
yes, with delay 
stop treatment 
total yes (%) 
other local side effei 
no 
yes, without delay 
yts, with dchy 
total yes (%) 
systemic side effects 
no 
yes, without deliv 
yes, with deliv 
stop treatment 
total ves (°/ ) 
:ts (p= 
(p<0 
122 
25 
1 
-
(17 6 ) 2 6 
141 
4 
1 
2 
(4 7 ) 7 
=0 004) 
141 
7 
-
(4 7 ) 7 
001) 
142 
6 
-
-
(4 1)6 
BCG Tice 
102 
26 
11 
1 
(27 1)38 
98 
40 
1 
1 
(30 0)42 
137 
2 
1 
-
(2 1 ) 3 
117 
23 
-
(16 4 ) 2 3 
102 
32 
3 
3 
(27 1)38 
BCG RIVM 
115 
24 
10 
-
(22 8) 34 
101 
45 
2 
1 
(32 2 ) 4 8 
146 
2 
1 
-
(2 0 ) 3 
127 
20 
2 
(14 8 ) 2 2 
122 
24 
1 
2 
(18 1)27 
total 
338 
75 
22 
2 
(22 7) 99 
321 
11 
4 
2 
(26 5) 116 
424 
8 
3 
2 
(3 0) 13 
385 
50 
2 
(11 9) 52 
366 
62 
4 
5 
( 1 6 3 ) 7 1 
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patients and 48% for BCG treated patients. This means that 22% of patients 
treated with Mitomycin-C and 52% of those treated with BCG were tumor-
free after 5 years. Our results are comparable for BCG patients. The percent-
age of patients free of tumor after 5 years was 54% of RIVM-BCG, 36% of 
Tice-BCG and 57% of Mitomycin-C treated patients. 
Although intravesical chemotherapy delays the time to first recurrence, it 
is unknown whether chemotherapy influences progression and survival. 
Recent studies suggest that the time to progression is prolonged with intra-
vesical immunotherapy in patients with superficial bladder cancer.1819 The 
progression rate in our study was low at 6%, 5% and 4% for Mitomycin-C, 
BCG-Tice and BCG-RIVM, respectively. Our data do not indicate that the 
progression rate to muscle-invasive disease was different in any of the 
treatment arms, which may explain the relatively low number of grade 3 and 
Tl tumors as well as the low number of carcinoma in situ patients. Most of 
the patients had intermediate risk tumors. Tumor grade did not significantly 
influence the time to treatment failure for any of the groups. 
Our study reports 84 patients with pTa grade 1 tumors. These low stage, low 
grade tumors have a low risk for recurrence or progression if they are solitary. 
Of the 84 pTa grade 1 patients, 43 had a solitary tumor and 41 had multiple 
primary or recurrent tumors. However, multiple pTa grade 1 tumors have an 
intermediate risk for recurrences, which indicates that in our study only 43 
of all eligible patients (9.8%) had a low risk for recurrence or progression. 
This also means that 90.2% of the patients may have had at least potential 
benefit of adjuvant intravesical therapy after transurethal resection. Therefo-
re, the significance of the results is not particularly diluted by inclusion of the 
10% of patients at low risk. 
Comparing a 6-week BCG schedule to 6 months of Mitomycin-C therapy, 
our data do not provide evidence that BCG offers better response in the 
treatment of patients with pTa and pTl bladder tumors than Mitomycin-C. 
In patients with primary or concomitant carcinoma in situ, immunotherapy 
with BCG also was not superior to chemotherapy with Mitomycin-C. How-
ever, the efficacy results in patients with carcinoma in situ, do not allow any 
conclusion to be drawn because too few patients with carcinoma in situ were 
entered in this study. 
This study does not address the issue whether a 6-week course of BCG is 
less effective than BCG maintenance therapy. However, it remains useful to 
look at the response rates in different studies in which 6-week courses, 
repeated 6-week courses or maintenance therapy have been used.4,19,20 Com-
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pansons with other reported studies must be interpreted with caution because 
of multiple variable factors, such as different doses, instillation schedules, 
selected patient groups and so forth. 
In Southwest Oncology Group study 8795 a randomized comparison of 
BCG-Tice and Mitomycin-C was performed in 469 patients.21 Of 377 
évaluable patients 37 tumor recurrences were documented in the 190 BCG 
treated patients (19.4%) versus 61 recurrences in the 187 Mitomycin-C 
treated patients (32,6%)(p=0.0052). The highly significant advantage of BCG 
over Mitomycine-C prompted early closure of the trial. However, in the 
Southwest Oncology Group trial at least 3 major differences can be noted 
compared to our study. In study 8795 only patients with rapidly recurring 
tumors (high risk) were enrolled, they were treated by maintenance therapy 
and the 20 mg dose of Mitomycine-C was low. 
Acknowledgements 
We thank Mr. Wim Lemmens (Department of Medical Statistics) for his 
assistance with the data processing, Dr. Ewout Schaafsma (Department of 
Pathology) for reviewing the histologic slides and Dr. Rime van Gils Gielen 
(Department of Urology) for the evaluation of the carcinoma in situ patients. 
58 
chapter 4 
REFERENCES 
1. Witjes JA, Van der Meijden АРМ and Debruyne FMJ (1990): Use of intrave­
sical Bacillus Calmette-Guérin in the treatment of superficial transitional cell 
carcinoma of the bladder: an overview. Urol. Int. 45: 129. 
2. Lamm DL, Thor DE and RadwinHM (1982): Bladder cancer immunotherapy. 
J. Urol. 128: 932. 
3. Pinsky CM, Camacho F, Kerr D, Braun DW jr., Whitmore WF jr. and Oettgen 
HF (1982): Treatment of superficial bladder cancer with intravesical BCG. In: 
Terry WD and Rosenberg SA, eds. Immunotherapy of human cancer. New 
York: Expcerpta Medica: 309. 
4. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino Ρ, Grossman 
HB, Stanisic ΤΗ, Smith JA Jr., Sullivan J, Sarosdy MF, Crissman JA and 
Coliman CA (1991): A randomized trial of intravesical doxorubicin and 
immunotherapy with bacillus Calmette-Guérin for transitional-cell carcinoma 
of the bladder. N. Engl. J. Med. 325: 1205. 
5. DeJagerR, Guiñan P, LammD, Khanna O, BrosmanS, DeKernion J, Williams 
R, Richardson BA, MuenzL,Reitsma D and Hanna MGjr. (1991): Long-term 
complete remission in bladder carcinoma in situ with intravesical Tice Bacillus 
Calmette-Guérin. Overview analysis of six phase II clinical trials. Urology 38: 
507. 
6. Herr HW (1987): Intravesical therapy. A critical overview. Urol. Clin. N. 
Amer. 14: 399. 
7. Huland H, Otto U, Droese M and Kloeppel G (1984): Long-term mitomycin 
С instillation after resection of superficial bladder carcinoma: influence on 
recurrence, progression, and survival. J. Urol. 132: 27. 
8. Bracke В, Johnson D, Von Eschenbach A, Swanson D, De Furia D and Crook 
S (1980): Role of intravesical mitomycin in management of superficial bladder 
tumors. Urology 16: 10. 
59 
9. Soloway MS (1987): Evaluation and management of patients with superficial 
bladder cancer. Urol. Clin. N. Amer. 14: 777. 
10. Debruyne FMJ, Van der Meijden АРМ, Geboers ADH, Franssen MPH, Van 
Leeuwen MJW, Steerenberg PA, de Jong WH and Ruitenberg JJ (1988): BCG 
(RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. 
First results of randomized prospective trial. Suppl. Urology 31:2. 
11. Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff 
EOand Dresner SM (1985)· Intravesical Bacillus Calmette-Guérin therapy for 
superficial bladder cancer: effect of Bacillus Calmette-Guérin viability on 
treatment results. J. Urol. 134: 48. 
12. Ratliff TL, Palmer JO, McGarr JA and Brown EJ (1987): Intravesical Bacillus 
Calmette-Guérin therapy for murine bladder tumors: initiation of response b> 
fibronectm-mediated attachment of Bacillus Calmette-Guérin. Cancer Res. 47: 
1762. 
13. Ratliff TL, Kavoussi LR, Catalone WJ (1988): Role of fibronectin in intravesi-
cal BCG-therapy for superficial bladder cancer. J.Urol. 139: 410-418. 
14. Hermanek P, Sobin LH (1987): TNM classification of malignant tumors. 
International Union Against Cancer. Fourth, fully revised edition. Heidelberg: 
Springer-verlag. 
15. Koss LG (1975): Tumors of the urinary bladder. Atlas of tumor pathology, 
2nd series. Fascicle 11, Washington D.C.: Armed Forces Institute of Pathology. 
16. Witjes JA, Van der Mei)den АРМ, Witjes WPJ, Doesburg W, Schaafsma HE, 
Debruyne FMJ (1993): A randomized prospective study comparing intravesi­
cal instillations of Mitomycin-C, BCG-Tice and BCG-RIVM in pTa-pTl 
tumors and primary carcinoma in situ of the urinary bladder. Eur.J.Cancer, 
vol. 29A.no. 12.1672. 
17. Lamm DL (1992): Long-term results of intravesical therapy for superficial 
bladder cancer. Urol.Clin.N. Amer. 19:573. 
60 
chapter 4 
18. Reitsma DJ, Guiñan Ρ, Lamm DL, Khanna OP, Brosman SA, DeKernion JB, 
Williams RD, Simpson G and Hanna MG jr. (1989): Long term effect of 
intravesical Bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in 
situ of the bladder. In: Debruyne FMJ, Denis L and Van der Meijden АРМ 
(eds.): BCG in superficial bladder cancer. Vol. 310 of Progress in clinical and 
biological research. New York: Alan R. Liss.: 179. 
19. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF 
jr., Fair WR and Oetggen HF (1987): A prospective randomized trial of 
maintenance versus non-maintenance intravesical Bacillus Calmette-Guérin 
therapy of superficial bladder cancer. J. Clin. Oncol. 5: 441. 
20. Hudson MA, Rathff TL, Gillen DP, Haaff EO, Dresner SM and Catalona WJ 
(1987): Single course versus maintenance Bacillus Calmette-Guérin therapy 
for superficial bladder tumors: a prospective, randomized trial. J. Urol. 138: 
295. 
21. Lamm DL, Crawford ED, Blumenstein J et.al. (1993): SWOG 8795: A 
randomized comparison of Bacillus Calmette-Guérin and Mitomycin-C prop-
hylaxis in stage Та and Tl transitional cell carcinoma of the bladder. J.Urol. 
149:4(275). 
61 
62 
chapter 5 
EFFECTS OF ISONIAZID ON THE BCG-INDUCED LOCAL 
IMMUNE RESPONSE AFTER INTRAVESICAL BCG-THERAPY 
FOR SUPERFICIAL BLADDER CANCER 
M.J J.G. Stassar, P.D.J. Vegr, P.A. Steerenberg, A.P.M, van der Mei|den, 
H.D. Meiring, M. Dessens-Kroon, H.G.M. Geertzen and W. den Otter 
Urological Research, 22:177-184, 1994 (with kind permission of 
Springer-Verlag GmbH & Co. KG, Heidelberg, Germany) 

chapter S 
ABSTRACT 
Because recent investigations showed that the use of Isoniazid severely 
impaired the local immune reaction to intravesical bacillus Calmette-Guérin 
(BCG) in the bladder of guinea pigs, in this study the effect of Isoniazid in 
man has been investigated. Patients were treated with BCG with or without 
oral Isoniazid. The concentration of free Isoniazid in most urine samples of 
patients treated with BCG/Isomazid was much higher (mean 38.0±60.9 pg 
Isoniazid/ml) than the minimal inhibitory concentration (MIC; 0.1 pg Isoni-
azid/ml), suggesting at least a bacteriostatic potential of the Isoniazid present. 
However, in vitro studies showed that these urinary concentrations of 
Isoniazid did not kill BCG organisms effectively, even at a concentration of 
150 pg/ml for 24 hours. After the fifth and sixth BCG-instillations a signifi-
cant increase in the concentration of cytokines (IL2, IL6, IL8 and TNFot), IgG 
and IgA antibodies to BCG and the number of leukocytes in urine was 
observed. The leukocytes mainly consisted of granulocytes, besides monocy-
tes/macro-phages and, in lower amounts, T- and B-lymphocytes and natural 
killer (NK) cells. The absolute number of granulocytes and the concentration 
of IgG antibodies after BCG-instillation were significantly suppressed by 
Isoniazid, whereas Isoniazid appeared to have no effect on the urinary 
cytokine and IgA antibody concentrations or the total number and phenotype 
of the leukocytes present. In conclusion, the results of this study indicate that 
Isoniazid does not impair the local immunological stimulation after BCG-in-
stillation in man as severely as was observed in the guinea pig and it may be 
expected that Isoniazid does not impair the antitumor efficacy of BCG. 
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INTRODUCTION 
Intravesical bacillus Calmette-Guénn (BCG) therapy is one of the most 
effective therapies for both prophylaxis and treatment of superficial bladder 
cancer.17 BCG belongs to the mycobacteria and is an attenuated strain of the 
bovine tubercle bacillus. The mode of action of BCG is probably based on 
local stimulation of the immune system,11'23 but the actual mechanisms by 
which BCG mediates antitumor activity are not clearly understood. 
Although BCG has lost its virulence, complications of intravesical BCG 
have been reported.1628 Side effects after intravesical instillation of BCG can 
be local (cystitis) or systemic, such as granulomatous prostatitis hepatitis, 
pneumonitis and even lethal sepsis.15 To diminish the local irritating bladder 
symptoms and to prevent systemic side effects, some urologists prescribe the 
bacteriostatic drug Isoniazid prophylactically. It has been assumed that 
Isoniazid will not influence the antitumor effect in man. However, the 
bacteriostatic potential of Isoniazid may reduce the effective dose of viable 
BCG organisms and thus reduce the antitumor activity.13 Recently the effect 
of Isoniazid treatment on the immune response after repeated intravesical 
BCG-instillation has been studied in guinea pigs.5 In that study the admini-
stration of Isoniazid severely impaired the immunological stimulatory effects 
of BCG. The induction of a mononuclear cell infiltrate in the bladder wall 
was reduced. Enlargement of the regional lymph nodes, and an increase of 
MHC Class II expression on the lymph node cells, normally observed after 
intravesical BCG-administration, were inhibited by Isoniazid. Systemic im-
munity to mycobacteria was also diminished. 
The influence of Isoniazid on the antitumor efficacy is now investigated 
in man (European Organisation for Research and Treatment of Cancer 
protocol 30911: comparative study of intravesical instillation of epirubicin, 
BCG or BCG plus Isoniazid in intermediate and high risk pTa-pTl papillary 
carcinoma of the urinary bladder). 
In previous studies we have investigated the local immunological effects after 
treatment of superficial bladder cancer patients with BCG by examining the 
urine on the presence of leukocytes and cytokines.2,34 
In the present study we have investigated the effect of Isoniazid on the 
local immune response induced by intravesical BCG-administration in pa-
tients with superficial bladder carcinoma. In the urine of patients treated with 
BCG or BCG/Isomazid the number of cells, the leukocyte subpopulations, 
and amounts of IL2, IL4, IL6, IL8, TNFa and of class IgG and IgA antibodies 
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to BCG were compared. The concentration of Isomazid in the urine and the 
effect of these concentrations on the viability of BCG were also determined. 
MATERIAL AND METHODS 
Patient treatment 
Urine specimens were obtained from 22 patients with superficial bladder 
carcinoma (stage pTa, pTl and/or carcinoma in situ) who were treated with 
BCG (Tice and RIVM) after transurethral resection of papillary tumor(s). 
BCG, approximately 5xl08 culturable particles, was administered in 50 ml 
0.9% saline once a week for six consecutive weeks. Twelve of the 22 patients 
investigated, also received 300 mg Isomazid orally the day before the BCG-
ìnstillation, 2 hours before instillation and on the day after instillation 
(instillation 1-6). After treatment with 6 instillations of BCG, patients were 
followed up by cytoscopy every 3 months. 
Collection and preparation of cells from urine 
Because previous investigations showed maximal urinary concentrations of 
cells and cytokines after repeated (>4) instillations,2 J 4 in this study urine 
specimens were examined during the 5th and 6th BCG-instillation. Samples 
were collected before instillation, 2 to 6 hours (pooled specimens) and 24 
hours thereafter. The specimens were centnfuged (5 min, 300g) and the 
supernatants were immediately frozen to -20°C and stored at -70°C. Super-
natants were afterwards thawed and used for measuring cytokines, antibodies 
and Isomazid. 
The cellular sediment was suspended in RPMI 1640 tissue culture medium 
(Gibco Europe B.V., Breda, The Netherlands), supplemented with 10% fetal 
calf serum (FCS; Gibco), penicillin (100 IU/ml) and streptomycin (100 pg/ml), 
referred to as complete RPMI. To obtain high cell viability all urine specimens 
were immediately cooled and processed at 4°C or on melting ice. After 
washing twice in complete RPMI, viable nucleated nonsquamous cells in 
urinary sediments were counted by trypan blue (0.5%) exclusion. The cells 
were used for immunofluorescence staining. 
Immunofluorescence staining 
Cells (5xl05) were labelled with 100 μΐ mAb in Dulbecco's Phosphate 
Buffered Saline (Gibco) with 0.01 % NaN, and 2% FCS, referred to as DPBS% 
in 96-well Microrest III Assay Plates (Becton Dickinson, Etten-Leur, The 
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Netherlands). Monoclonal antibody (MAb) FK32 (anti-CD15; granulocytes) 
was kindly provided by Dr. F. Koning (University of Leiden, Leiden, The 
Netherlands). Other mAbs were obtained from Becton Dickinson: anti-HLEl 
(anti-CD45, leukocytes), anti-LeuM3 (anti-CD14, monocytes/macrophages), 
anti-Leu 12 (anti-CD19, B-lymphocytes), anti-Leu4 (anti-CD3, T-lymphocy-
tes), anti-Leu3 (anti-CD4, helper/inducer T-lymphocytes), anti-Leu2 (anti-
CD8, suppressor/cytotoxic T-lymphocytes), ant i-Leul lc (anti-CD16, NK 
cells), anti-Leul9 (anti-CD56, NK cells), anti-IL2R (anti-CD25, IL2-recep-
tor), anti-HLA-DR (la non-polymorphic), anti-TCR-1 α/β (T-cell receptor-
α/β), anti-TCR-7/δ-Ι (T-cell receptor-7/δ). Fluorescein isothiocyanate 
(FITC)-conjugated F(ab'), fragments from rabbit anti-(mouse Ig) (Organon 
Teknika, West Chester, Pa, USA) were used as second Ab to detect binding 
of FK32. All other mAbs were conjugated to either FITC or phycoerythrin 
(PE). As negative controls, mAb of irrelevant specificity (anti-KLH) but 
corresponding isotypes (Becton Dickinson) or FITC-conjugated rabbit anti-
(mouse Ig) mAb only, were used. Labelled cells were finally fixed in 200 μΐ 
paraformaldehyde solution (0 .25% in DPBS+). 
Flow cytofluorometry and analysis 
Samples of l x l O 4 cells were measured with a fluorescence-activated cell sorter 
(FACScan, Becton Dickinson Immunocytometry Systems, Mountain View, 
California, USA). During measurement the forward scatter threshold was set 
on channel 52 for background exclusion. Quantification of granulocytes, 
monocytes/macrophages, and T- and B-lymphocytes was based on cells with 
forward scatter >200. The fluorescence of the granulocytes and the monocy­
tes/macrophages was determined in the fluorescence histogram of the total 
cell population. Analysis of lymphocyte subsets was made possible by a 
selective cell measurement procedure to increase the number of cells within 
the lymphocyte gate 2 The number of cells within the lymphocyte gate 
reacting with a specific mAb is expressed as percentage of the CD45 + cells 
(leukocytes) within the gate. However, in eleven of the fifteen urine sediments 
of patients treated with BCG and in ten of the twenty sediments of patients 
treated with BCG/Isoniazid, the leukocytes present just before the BCG-in-
stillation could not be analyzed because of low cell numbers. 
Detection of IL2, IL4, IL6, IL8, TNFu 
and antibodies specific to BCG 
IL4, IL6 and T N F a were determined using specific enzyme-linked immuno­
sorbent assays (ELISA) from Medgenix (Fleurus, Belgium). 
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For detection of IL2 a specific bioassay with the IL2-dependent murine T-cell 
line CTLL-16 was used as previously described.1 2 A human recombinant IL2 
preparation was used as a standard (Proleukin; EuroCetus Benelux B.V., 
Amsterdam, The Netherlands). IL8 was measured with an ELISA according 
to a procedure described previously.9 The detection limits of the various 
assays were 0.1 IU IL2, 2 pg IL4, 3 pg IL6, 5 pg IL8, and 3 pg TNFa per ml 
urine. The results were standardized to urine creatinine levels (pg/μΓηοΙ 
creatinine). Urine creatinine was determined photometrically (500 nm) with 
a Cobas-Βίο centrifugal analysator (Hoffmann-La Roche Ltd., Basle, Swit-
serland), using alkaline pikrate as reagent. The mean creatinine concentration 
for all samples was 9.76+5.18 («=252). 
Class IgG and IgA antibodies to BCG were determined with an ELISA.1 4 
For this purpose flat bottomed ELISA microplates (Greiner, Alphen a/d Rijn, 
The Netherlands) were coated with 100 μΐ carbonate buffer containing 10 
pg/ml purified protein derivative (PPD) of Mycobacterium tuberculosis. 
Isoniazid determination 
For determination of Isoniazid, urine was collected just before, 2-6 hours 
after (pooled specimens), and 24 hours after the BCG-instillation. After 
centrifugation (5 min, 300g) the supernatant was stored at -70CC until 
analysis. Analysis of Isoniazid was based on acetylation of Isoniazid with 
pentafluorobenzoylchlonde in an aqueous solution, resulting in the forma­
tion of 2-(4-pyndyl)-5-pentafluorophenyl-l, 3, 4-oxadiazole. Quantification 
was performed using benzoic hydrazide as internal standard. Both derivatives 
have favourable electron capture properties and can be analyzed with high 
sensitivity with Negative Ion Chemical Ionization GC/MS, monitoring their 
molecular ions [M]-. 
Effect of urinary Isoniazid concentrations on BCG viability 
The direct cidal effect of Isoniazid to BCG was determined in a quantitative 
suspension test. Approximately 1.2xl0 7 colony forming units (cfu)/ml PBS 
were exposed to 0, 50 or 150 μg/ml Isoniazid. After 24 hours Isoniazid was 
inactivated with 0 .5% pyruvate. Hereafter mycobacteria were cultured on 
Middlebrook 7 H 1 0 medium The number of cfu was counted after 4 weeks 
of growth at 35°C in 5 % C O
v 
Statistical analysis 
Significance of differences between the total cell number, number of cells in 
various cell subsets, cytokine- and antibody-concentrations before and after 
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treatment within each group of patients (BCG or BCG/Isoniazid) was deter­
mined with Two Sample Sign test for Equal Medians. 2 6 Differences between 
the percentages of cells (determined by flow cytometric analysis), the number 
of cells and the amount of cytokines and antibodies in BCG- and BCG/Isoni-
azid treated patients were statistically determined with Mann-Whitney two 
sample (non-matched) test.2 6 
RESULTS 
Urinary Isoniazid concentration and effect on BCG viability 
Isoniazid was administered orally the day before, two hours before and the 
day after BCG-instillation. The concentration of Isoniazid in urine was 
measured just before, 2-6 hours after (pooled urine specimens), and 24 hours 
after the fifth BCG-instillation (Figure 1). Although Isoniazid concentrations 
showed large variations between individual patients, nearly all concentrations 
were far higher (mean: 38.0±60.9 pg Isoniazid/ml) than the minimal inhibi­
tory concentration (MIC; 0.1 μg/ml) determined for BCG in vitro by the agar 
dilution technique (after 21 days of incubation with Isoniazid, the number of 
colony forming units of BCG was counted). 1 4 Only one patient showed no 
detectable urinary Isoniazid concentrations just before and 24 hours after 
BCG-instillation. As a negative control, Isoniazid was also measured in urine 
of two patients treated with BCG only. In these samples no Isoniazid could 
be detected (data not shown). To study the effect of high Isoniazid concen­
trations on the viability of BCG, fresh mycobacteria were incubated with 0, 
50 and 150 pg/ml Isoniazid, comparable to Isoniazid concentrations found 
in the urine after the fifth BCG-instillation (Figure 1). Four weeks after 
addition of Isoniazid during 24 hours to a BCG culture, none of the Isoniazid 
concentrations tested appeared to be bactericidal to the mycobacteria (Table 
1). 
Table I tffect of Isoniazid on bacillus Calmette-Guerm organisms exposure (24h) 
( oncentration of Isoniazid (μ^πιΐ) 
0 
SO 
ISO 
Number (x 10 ) of colony-forming 
units of BCG 
6 0 
7/S 
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Figure î. Isoniazid concentration in urine before (0 hrs), 2-6 hrs after and 24 hrs after fifth 
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Figure 2. Total number of leukocytes before (0 hrs) and 24 hrs after fifth and sixth BCG and 
BCG/lsonia/id instillation (determined by trypan blue exclusion). - mean number of cells. The 
number of cells is significantly increased 24 hours after BCG-instillation, ** P<0.01 (two 
sample sign test). 
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Effect of Isoniazid on urinary cell numbers 
Before the fifth and sixth BCG-instillation, the number of viable cells in urine 
from patients treated with BCG or BCG/Isoniazid ranged from l.OxlO 2 to 
7.1xl05/ml and from 1.7xl0 2 to 1.5xl06/ml, respectively. In both groups of 
patients (BCG and BCG/Isoniazid) the total number of cells in the urine was 
significantly (P<0.01) higher 24 hours after BCG-instillation than before 
instillation (Figure 2). 
Effect of Isoniazid on leukocyte subpopulations 
The relative quantities of leukocyte subpopulations of urine sediments before 
and after the fifth and sixth BCG-instillation, determined by flow cytofluoro-
metry, are presented in Table 2. Granulocytes (CD15+) were predominant 
(about 67%), in addition to which about 3 % of monocytes/macrophages 
(CD14+), and about 1% T- lymphocytes (CD3+) were found. B-lymphocytes 
(CD19+) and NK-cells (CD56+) were present in very small amounts or even 
absent (between 0 % and 0.5%). 
Table 2 shows that after both BCG and BCG/Isoniazid treatment the 
percentage of monocytes/macrophages had increased significantly by 24 
hours after BCG-instillation compared to pre-instillation values (P<0.05). 
The percentage of Τ helper/inducer cells (CD4+) was significantly decreased 
24 hours after BCG-treatment, but not after BCG/Isoniazid treatment. This 
decrease was probably caused by high pre-instillation values, in which case 
it is not relevant. The two groups of patients (BCG and BCG/Isoniazid) did 
not differ significantly in the percentage of leukocytes either before or 24 
hours after BCG-instillation. 
For both treatments (BCG and BCG/Isoniazid) the mean percentage of Τ 
suppressor/cytotoxic (CD8+) was lower than the percentage CD4+-cells both 
before and 24 hours after BCG-instillation (Table 2). Before and after BCG 
or BCG/Isoniazid treatment most of the lymphocytes expressed α/β T-cell 
receptor (TCR) and a considerable percentage of T-cells showed HLA-DR 
and IL2-receptor (CD25) expression. N o indications were found for different 
percentages of α/β TCR, HLA-DR or IL2-receptor expression between 
samples of patients treated with BCG and patients that received BCG/Isoni-
azid. However, when the absolute number of leukocyte subpopulations are 
calculated, Isoniazid induced no significant increase of the absolute number 
of granulocytes 24 hours after BCG-instillation, whereas the absolute num­
bers of monocytes/macrophages, T-cells and B-cells were significantly 
(P<0.05) increased 24 hours after both treatments (BCG and BCG/Isoniazid) 
(Figure 3). 
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Table 2. Leukocyte subpopulations and subsets of lymphocytes in urine before (0 hrs) and 
after (24 hrs) fifth and sixth BCG-instillation. Percentages given are mean ± s.d. of (n) patients. 
* P<0.05 (Mann-Whitney) for difference between Oh and 24h. 
Cell type 
Granulocytes* 
Monocytes/ 
macrophages 5 
Τ lymphocytes'1 
И lymphocytesb 
NK cells'1 
Τ helper/ 
inducer''·'' 
Τ suppressor/ 
cytotoxic1 1 ' 
IL2 receptor11"' 
HLA-DRb* 
α/βΤ cell 
receptor*1'' 
•γ/δ Τ cell 
receptor*1·1 
CD4/CD8 ratio 
0 
68 ± 10 
(4) 
1 ± 0 
(4) 
1 ± 1 
(4) 
0 ± 0 d 
(4) 
0 ± Od 
(4) 
64 ± 13 
(3) 
1 6 * 2 
(3) 
37 ± 3 2 
(3) 
67 ± 3 0 
(3) 
81 ± 13 
(3) 
17± 13 
(3) 
4.0 ± 1.3 
(3) 
Cell composition 
BCG 
24h 
63 ± 18 
(14) 
3 ± 2 ' 
(14) 
1 ± 1 
(14) 
0 ± 0 d 
(14) 
0 ± 0 d 
(14) 
38 ± 16* 
(14) 
18 ± 8 
(14) 
16± 11 
(14) 
50 ± 2 1 
(14) 
58 ± 2 6 
(14) 
9 ± 9 
(14) 
2.5 ± 1.9 
(14) 
(%) after 
BCG/Isoniazid 
0 24h 
71 ± 13 
(10) 
2 ± 2 
(10) 
1 ± 1 
(10) 
0 ± 0 d 
(10) 
0 ± 0 J 
(10) 
44 ± 19 
(8) 
1 9 ± 9 
(8) 
20 ± 12 
(7) 
47 ± 2 2 
(8) 
56 ± 2 1 
(8) 
5 ± 4 
(8) 
3.3 ± 3.2 
(8) 
65 ± 14 
(17) 
6 ± 4 ' 
(17) 
1 ± 0 
(17) 
0 ± 0 J 
(17) 
0 ± 0 J 
(17) 
39 ± 15 
(17) 
19± 11 
(17) 
21 ± 17 
(17) 
55 ± 15 
(17) 
61 ± 2 1 
(17) 
7±8 
(17) 
2.5 ± 1.2 
(17) 
1
 Determined by flow cytometric analysis of the total cell population with forward scatter 
>200. 
' Determined by flow cytometric analysis of the cells in the lyphocyte gate. 
" Positive cells expressed as percentage of the CD45* cells. 
J
 Percentages 0 - 0.5%. 
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Table 3. Increase of concentrations IL2, IL6, IL8 and TNFa after fifth and sixth BCG-instil-
lations, with and without Isoniazid. Values shown are means ± S.D. for (n) specimens of 
concentrations 24h after instillation minus concentration before. Differences are not signifi­
cant. 
Cytokine 
IL2 
IL6 
IL8 
TNFa 
Treatment 
BCG 
BCG/Isoniazid 
BCG 
BCGЯsoniazid 
BCG 
BCG/Isoniazid 
BCG 
BCG/Isoniazid 
Increase 
0.79 ± 1.07(13) 
0.49*0.51 (17) 
146 ±283 (15) 
61 ±78(19) 
799 ±883 (15) 
345 ±471 (19) 
224 ±327 (15) 
35 ± 5 3 (19) 
Effect of Isoniazid on urinary concentrations of IL2, IL4, IL6, 
IL8 and TNFa 
Figure 4 shows the levels of IL2, IL6, IL8 and TNFot in urine before and 2-6 
hours after (obtained from pooled urine samples) the fifth and sixth BCG-in-
stillation. In most pre-instillation samples the concentration of IL2 and T N F a 
were low or not detectable. In contrast, the levels of IL6 and IL8 in urine were 
relatively high just before BCG-instillation, ranging from 0 to 12.8 pg 
IL6/pmol creatinine and 0 to 254 pg IL8/pmol creatinine. 
The concentration of urinary IL2, IL6, IL8 and T N F a showed a significant 
increase during 2-6 hours after BCG-instillation in both groups of patients 
(P<0.01). However, there were considerable variations between individual 
patients with respect to the concentrations during 2-6 hours after BCG or 
BCG/Isoniazid treatment. In none of the urine samples tested were detectable 
IL4 concentrations both before and 2-6 hours after BCG or BCG/Isoniazid 
found (data not shown). The increase of urinary cytokine concentrations after 
the fifth and sixth BCG-instillation can be seen from Table 3, showing no 
significant differences between BCG and BCG/Isoniazid treatment. 
Effect of Isoniazid on urinary concentrations 
of anti-BCG IgG and IgA antibodies 
The presence of urinary IgG and IgA antibodies to BCG is presented in Table 
4. Anti-BCG IgG and IgA were present before the fifth and sixth instillation 
of both treatments (BCG and BCG/Isoniazid). The concentration of urinary 
IgA was significantly increased (P<0.01) 2-6 hours after BCG and BCG/Iso-
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Table 4. Presence of BCG-specific IgG and IgA antibodies in urine before (0 hrs) and after (2-6 
and 24 hrs) the fifth and sixth BCG-instillations [ mean ± s.d. for η samples; 1U = [(OD (450 
nm)-background OD (450 nm)) /mmol creatinine] χ 1000; ** P<0.01 (two-sample sign test)] 
Treatment Time 
h 
BCG _ 0 _ 
2-6 
24 
BCT^somazid _0_ 28.24 a 31.32 (20) 6.91 ± 9.35 (20) 
2-6 38.02 ±41.63 (20) 9.96 ± 11.50 (20)" 
24 10.92 ±23.38 (20) 2.46 ± 2.90 (20) 
niazid treatment. Also IgG was significantly increased (P<0.01) 2-6 hours 
after BCG-treatment, whereas after BCG/Isoniazid treatment no significant 
increase could be found. By 24 hours after both BCG and BCG/Isoniazid 
treatment the concentrations of IgG and IgA decreased. 
DISCUSSION 
In the present study we investigated the effect of oral Isoniazid administration 
on local cellular immunological stimulation after 5 and 6 intravesical BCG-
instillations in man. The great majority of individuals can be characterized 
as either slow or rapid inactivators of Isoniazid.19 The large variations 
observed in Isoniazid concentrations between individual patients may indi­
cate the presence of slow and fast inactivators of Isoniazid in this study (Figure 
1). The concentration of free Isoniazid in most urine samples was far higher 
than the minimal inhibitory concentration as determined for BCG in vitro 
(0.1 pg/ml),18 suggesting a bacteriostatic potential of the intravesical Isonia­
zid. The minimal inhibitory concentration was determined by the agar 
dilution technique, in which the number of cfu of BCG was counted after 21 
days of incubation with Isoniazid. As shown in Figure 1, Isoniazid is present 
in urine only for about 24 hours. The consequences of these temporary high 
urinary Isoniazid concentrations were studied in vitro (Table 1), showing no 
short term bactericidal activity of Isoniazid to BCG. 
Concentration (U) of antibodies 
JgG IgA 
i \-Ж* H.95 (15) 7.63 ± 7.26 (15) 
87.74 ± 81.27 (15)" 27.82 ± 35.99 (15)*» 
21.08*25.29(15) 4.68 ± 5.29 (15) 
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Both BCG and BCG/Isoniazid administration induced a significant increase 
in the total number of leukocytes in the urine 24 hours after BCG-instillation 
(Figure 2). However, when the cell number after the sixth instillation is 
determined separately from the fifth instillation, the increase after 24 hours 
was significantly inhibited by Isoniazid after the sixth instillation, but not 
after the fifth instillation (data not shown). 
The absolute and relative amounts of leukocytes and leukocyte subsets 
after intravesical BCG therapy are in agreement with observations of De Boer 
et al..2 Although the percentage of granulocytes, B-cells and T-cells 24 hours 
after BCG-instillation showed no significant increase (Table 2), the absolute 
numbers of the leukocyte subsets were significantly increased after BCG-in-
stillation (Figure 3). These findings are comparable with results reported by 
De Boer et al..3 In contrast to the relative low T-cell number in the urine after 
both treatments (BCG and BCG/Isoniazid), T-lymphocytes are the main cell 
type present in bladder wall infiltrates in patients after intravesical BCG-ad-
ministration.6 20 This is possibly the result of differences in time of sample 
collection after BCG-treatment. Because T-lymphocytes have been shown to 
play an important role in the antitumor activity of BCG,1021'22 subsets of 
lymphocytes in urine after intravesical BCG-administration have been cha-
racterized. Both before and 24 hours after BCG-instillation, T-cells showed 
expression of HLA-DR andIL2-receptors, indicating activation of T-lympho-
cytes. The presence of the activation markers HLA-DR and IL2 receptor is 
in accordance with their presence in bladder wall biopsies.6'20 This suggests 
that the lymphocytes in the urine are probably a reflection of the events which 
take place in the bladder wall after BCG-administration. 
After both BCG and BCG/Isoniazid treatment the levels of IL2, IL6, IL8, 
and TNFa showed a significant increase during 2-6 hours after BCG-admi-
nistration. These data are in agreement with results of other studies on 
cytokines in urine after BCG-treatment.1'47'12'21,24 However, when cytokine 
concentrations of the fifth and sixth instillation are determined separately, 
the increase of IL8 and TNFa was significantly reduced by Isoniazid after the 
fifth instillation (data not shown). After the sixth instillation no significant 
differences between BCG and BCG/Isoniazid treatment could be observed 
(data not shown), suggesting probably a transient reduction of the cytokine 
induction by Isoniazid. The absence of IL4 in urine after both treatments 
(BCG and BCG/Isoniazid) probably indicates the absence of the Th2 subset 
of CD4+ T-cells. It has been shown that mycobacteria can selectively induce 
human T-cells with a Thl-like cytokine secretion profile.8 The release of 
BCG-specific antibodies of both IgA and IgG classes after intravesical BCG-
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administration was also found by Van Der Sloot et al..27 Probably, these 
antibodies may lead to lysis of mycobacteria by opsonization and subsequent 
increased phagocytosis by granulocytes.29 
In conclusion, the antitumor activity of BCG has been reported to be 
dependent on the dose of viable mycobacteria.13'25 In our study, Isoniazid 
(tested with concentrations comparable to those found in urine after the fifth 
instillation) did not kill BCG organisms. Furthermore, Isoniazid did not 
impair the local immunological effects after BCG-instillation as has been 
reported in guinea pigs.5 Although Isoniazid may inhibit the proliferation of 
BCG because the urinary concentrations found were much higher than the 
minimal inhibitory concentration, viable BCG organisms are still able to 
induce the observed local immune response and antitumor activity. If Isoni-
azid does not influence the immunological action of BCG, it may be expected 
that Isoniazid does not impair the antitumor efficacy of BCG. If this assum-
ption is true and if Isoniazid would inhibit the potential side effects of BCG, 
then the use of prophylactical Isoniazid would improve therapy of intravesi-
cal BCG in patients with superficial bladder cancer. Both issues are now 
investigated in man. 
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ABSTRACT 
Purpose: We analyzed the influence of the tuberculostatic agent Isoniazid on 
the incidence and severity of adverse effects of intravesical bacillus Calmette 
Guenn (BCG) therapy in patients with superficial bladder cancer. 
Material and methods: In a prospective randomized multicenter study, the 
side effects of intravesical instillations with Tice-strain BCG with and without 
Isoniazid were compared in patients with stages pTa and pTl bladder tumors. 
Isoniazid was given orally in a dose of 300 mg daily at every instillation in 
an attempt to decrease the side effects of BCG. 
Results: No differences in local or systemic adverse reactions after intravesical 
immune therapy with BCG could be observed between patients treated with 
or without prophylactic Isoniazid therapy. However, analysis of liver func-
tion tests after BCG with Isoniazid showed slightly more liver toxicity 
compared to BCG alone. 
Conclusions: Prophylactic administration of Isoniazid during BCG-instilla-
tions provides no decraese in any known side effect of BCG. In contrast, 
transient liver function disturbances are encountered slightly more frequently 
when Isoniazid is administered. The use of prophylactic Isoniazid in patients 
treated with BCG is not recommended. 
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INTRODUCTION 
Intravesical nonspecific immunotherapy with bacillus Calmette-Guérin 
(BCG) was introduced in 1976 by Morales et al.,1 and has proved to be a 
highly effective treatment of and prophylaxis for recurrent stages pTa and 
pTl bladder tumors. Most reports have claimed that BCG is superior to 
intravesical chemotherapy and, therefore, that it is one of the most effective 
agents currently available for the prophylactic treatment of stages pTa and 
pTl bladder cancer.2,3 However, in several studies this superiority of BCG 
intravesical treatment could not be demonstrated.4·5 
Although BCG has been proved to be very effective, particularly for high 
risk superficial bladder cancer patients, some urologists are reluctant to use 
BCG because of the more pronounced adverse reactions reported in the 
literature.5 This fear seems to be justified because approximately 5% of 
patients treated with BCG will have substantial adverse reactions,6 while 30 
to 50% may have minor local or systemic side effects. Therefore, the question 
remains whether it would be possible to decrease the toxicity of BCG without 
impairing the antitumongenic effect. Reduction of the dose of BCG may be 
possible. Pagano et al. reported that low dose (75 mg) Pasteur strain BCG 
was as effective as standard dose (150 mg) BCG, but that the toxicity appears 
to be significantly less.7 Others have confirmed these results.8,9 Another 
possibility could be the prophylactic administration of tuberculostatic agents 
at each BCG-instillation. 
BCG is the attenuated strain of mycobactenum bovis. Although the 
virulence has been controlled, its antigenetic properties and sensitivity to 
tuberculostatic agents have remained unimpaired.10 Tuberculostatic agents, 
such as Isoniazid, are used to diminish or to treat the local irritative symptoms 
and systemic side effects caused by intravesical BCG.11 In 4 different BCG-
strains (BCG-RIVM, BCG-Tice, immune Pasteur and Connaught) the suscep-
tibility to Isoniazid and other tuberculostatic agents has been tested in vitro. 
All BCG preparations were equally susceptible to Isoniazid.12 Isoniazid is 
secreted in the urine, which means that if the concentration of Isoniazid in 
the bladder is appropriate, the drug might be able to kill living BCG bacilli 
in the bladder. However, the sensitivity of BCG for Isoniazid mav influence 
the antitumongenic efficacy of BCG-therapy. In animal models the use of 
Isoniazid has been shown to impair the immunological response of intrave-
sical BCG.11 A recent study in man indicated that Isoniazid might not impair 
local immunological stimulation after intravesical BCG-admimstration.14 
Whether Isoniazid decreases the antitumor effect of BCG in man is unknown. 
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The precise role of Isoniazid when used prophylactically in patients treated 
with BCG was subject to investigation in European Organization for Re-
search and Treatment of Cancer protocol 30911. The 2 objectives of this trial 
were to assess whether Isoniazid decreases local and systemic side effects, as 
well as the antitumongenic effect in patients treated with intravesical BCG. 
We addressed the former question, while the latter cannot yet be answered 
because the study is still ongoing. 
MATERIALS AND METHODS 
After complete transurethral resection patients with intermediate and high 
risk superficial bladder cancer were entered into this 3 arm multicenter 
randomized phase HI study and randomized to receive epirubicin, or Tice-
strain BCG alone or with prophylactic Isoniazid. No placebo was used in the 
BCG only arm so that the study was not blinded with respect to the assessment 
of adverse events. 
Tice-strain BCG (5xl08 bacilli) was administered for 6 consecutive weeks 
followed by 3 weekly instillations at months 3, 6, 12, 18, 24, 30 and 36, 
according to the maintenance schedule reported by Lamm et al..3 The first 
instillation was administered 7 to 15 days after transurethral resection of the 
bladder tumors. Isoniazid (300 mg) was given orally on the day before, 2 
hours before and the day after each instillation. 
The adverse reactions in the BCG arms were divided into local (bladder 
related) and systemic side effects. The severity of these side effects were 
classified as none, not requiring a delay, requiring a delay, or requiring 
cessation of instillation therapy. The complaints and symptoms were recor-
ded before and after each instillation. Specific questions were asked by the 
urologist or study personnel about the presence or absence of local and 
systemic side effects. The baseline incidence of local complaints was noted to 
obtain more insight into the possible adverse effects of BCG-therapy. 
Local toxicity was classified as bacterial cystitis - the occurrence of culture 
proven (not BCG) bacterial cystitis, drug induced or chemical cystitis -
irritative symptoms with negative urine culture and other local side effects -
hematuria, granulomatous prostatitis, epididymo-orchitis and ureteral ob-
struction. 
Systemic side effects were classified as fever (more than 39° C), influenza-
like symptoms (general malaise and chills), pneumonitis, hepatitis, cytopenia 
and sepsis. Skin rash, arthralgia and migratory arthritis were classified as 
possible allergic reactions. 
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For evaluation of toxicity patient complaints were noted, urine analysis with 
urine cultures were performed and liver function tests (alkaline phosphatase, 
aspartate and alanine aminotransferases, and gamma-glutamyl transpeptida-
se) were done during each bladder instillation. Based on the seventy of adverse 
effects, the treating physician decided whether no action was to be taken, 
instillations were to be postponed or BCG-therapy was to be definitively 
stopped. 
From the start of the study in January 1992 until September 1996 (cut off 
point), a total of 868 patients were entered into this still ongoing study: 289 
were randomized to receive Epirubicine, 290 patients and 289 to receive BCG 
with and without Isoniazid respectively. The toxicity data for BCG alone and 
with Isoniazid were evaluated. Data concerning the toxicity of epirubicin 
were not addressed in this analysis. 
Toxicity data were available for 436 patients: 224 in the BCG only group 
and 212 in the BCG plus Isoniazid group. Because the trial is still ongoing 
and recruiting patients, no followup data were available for recently entered 
patients. Values which are missing (unknown) caused a slight variation in the 
total column (number of patients) in the tables. The numbers of treatment 
cycles (6 or 3 weeks BCG) evaluated in this analysis was 751 for BCG alone 
and 671 for BCG with Isoniazid. 
In each case the maximum degree of toxicity during treatment was 
assessed. The percentage of patients with a given toxicity in the 2 study arms 
was compared using a 2 sided chi-square test. For ordered categorical 
variables, a chi-square test for trend to compare the average maximum degree 
of toxicity was also done. The maximum change in the liver function tests 
with respect to baseline was compared using the Kruskal-Wallis test 
RESULTS 
Local side effects (bladder related) 
The local side effects are shown in Table 1. Frequent micturition (more than 
1 time per 2 hours) was the most frequent local toxicity observed, and 
occurred in 119 of 223 (53%) and 105 of 201 (50%) patients given BCG 
alone or with Isoniazid, respectively (p=0.51 ). The second most frequent local 
side effect was chemical cystitis, which occurred in 89 of 223 (40%) and 77 
of 221 (36%) patients, respectively (p=0.53). The administration of BCG had 
to be stopped because of chemical cystitis in 11 patients in each treatment 
group Bacterial cystitis (culture proved) was observed in 50 of 220 (23%) 
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Table I . Local and systemic side effects of intravesical BCG alone versus BCG with Isoniazid. 
frequency 
BCG 
BCG plus Isoniazid 
p = 0 51 
< 1 per 2 hours 
104 
106 
> 1 per 2 hours 
119(53%) 
105 (50%) 
total 
223 
211 
210 224 (52%) 434 
No side Side effects: Side effects: Side effects total 
effects no delay of delay stop 
instillations instillations instillations 
Chemical Cystitis 
BCG 
BCG plus Isoniazid 
p=0.53 (%) 
p=0 97 (trend) 
Bacterial Cystitis 
BCG 
BCG plus Isoniazid 
p=0.74(%) 
p=0 74 (trend) 
Granulomatous prostatitis, 
epididymo-orchitis or 
ureteral obstruction 
BCG 
BCG plus Isoniazid 
p=0 89(%) 
p=0 38 (trend) 
134 (60%) 
134 (64%) 
268 (62%) 
70 
53 
123 
8 
13 
21 
11 
11 
22 
223 
211 
434 
170 (77%) 
166 (79%) 
336 (78%) 
26 
22 
48 
22 
20 
42 
2 
2 
4 
220 
210 
430 
163 (73%) 45 
152 (72%) 38 
315 (73%) 83 
11 
20 
10 
16 
223 
211 
434 
Hematuria 
BCG 
BCG plus Isoniazid 
p = 029 
No 
148 
151 
299 
Yes 
75 (34%) 
60 (28%) 
135 (31%) 
total 
223 
211 
434 
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and 44 of 210 (21%) patients given BCG alone or with Isoniazid, respectively 
(p=0.74). The instillations were delayed because of bacterial cystitis in 22 and 
20 patients, respectively, and had to be stopped in two patients in each group. 
The incidence of hematuria was also not significantly different between the 
2 groups, and occurred in 75 of 223 (34%) and 60 of 211 (28%) patients, 
respectively (p=0.29). Other known BCG related local side effects, such as 
granulomatous prostatitis, epididymo-orchitis and ureteral obstruction, had 
the same incidence in both groups (27% and 28%, respectively, p= 0.89). 
Thus, the incidence of local side effects did not differ significantly between 
patients treated with BCG alone or with Isoniazid. 
Systemic side effects 
Fever of more than 39°C occurred in 25 of 224 (11%) and 31 of 211 (15%) 
patients given BCG alone or with Isoniazid, respectively (p=0.34) (Table 1). 
Influenza-like symptoms (general malaise and chills) were reported in 39 of 
224 (17%) and 45 of 210 (21%) patients, respectively (p=0.35). 
In regard to allergic reactions, skin rash occurred in 5 of 224 (2%) and 6 
of 211 (3%) patients, respectively. Arthralgia and migratory arthritis were 
not reported in this study. These data show that there is no statistically 
significant difference in the incidence of the systemic side effects such as fever 
(greater than 39°C), influenza-like symptoms and allergic reactions. 
However, liver function values for aspartate aminotransferase after treat-
ment were different between the 2 groups. In the group treated with BCG 
plus Isoniazid, values greater than 1.25 times normal for aspartate and 
alanine aminotransferases were observed twice as often as in patients who 
did not receive Isoniazid (Table 2). For aspartate aminotransferase the 
difference was statistically significant (p=0.05). If only patients with an initial 
value of aspartate aminotransferase of less than 1.25 times normal are 
analysed, then 12 of 168 (7%) on BCG alone and 23 of 157 (15%) on BCG 
plus Isoniazid had an increase in their aspartate aminotransferase values to 
more than 1.25 times normal during followup (p = 0.05). Patients on BCG 
plus Isoniazid also showed a greater degree of change in aspartate ami-
notransferase between the baseline value at entry and the maximum degree 
of elevation during treatment (p = 0.03). There were no cases of pneumonitis 
or sepsis. 
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Table 2. Liver function tests before and during intravesical treatment with BCG alone or with 
Isoniazid. 
No. Pts. With Value More ρ Value 
Than 1.25 Times 
Normal*/Total (%) 
BCG Alone BCG with 
Isoniazid 
Alkaline phosphatase: 0.81 
Before treatment 2/218(1) 3/216(1) 
During treatment H/203 (7) 12/191(6) 
Aspartate aminotransaminase: 0.05 
14/193 (7) 26/187(14) 
0.12 
0/217(0) 
9/190 (5) 
3/215(1) 
17/181 (9) 
0.81 
8/183(4) 13/185(7) 
Before treatment 3/214(1) 8/215(4) 
During treatment 
Alanine aminotransaminase: 
Before treatment 
During treatment 
Gamma-glutamyl transpeptidase: 
Before treatment 
During treatment 28/177(16) 30/173(17) 
* For local laboratory. 
DISCUSSION 
BCG has no direct toxic effect on tumor cells but stimulates a cascade of 
immune reactions that results in tumor destruction. BCG is a living organism 
that can produce not only local bladder related and local inflammatory 
reactions, but also systemic side effects.6 
Isoniazid is used as a tuberculostatic agents in patients with active lung 
tuberculosis. One of the objectives of our study was to investigate whether 
prophylactic short-term Isoniazid administration can decrease the side effects 
of intravesical BCG-therapy while maintaining antitumorigenic efficacy. In 
this analysis the side effects of BCG only were compared to those of BCG 
plus prophylactic Isoniazid administration during 3 days at each instillation. 
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However, the administration of Isoniazid itself can produce adverse reactions 
as well, particularly liver function disturbances. The reported adverse reac-
tions after Isoniazid administration used for the treatment of active tubercu-
losis may include gastro-intestinal complications, peripheral neuropathy and 
mild neurologic disorders. Liver function enzymes may increase in 10 to 20% 
of the patients. In most cases this condition is asymptomatic.15 However, in 
treating active tuberculosis Isoniazid is administered in a daily dose of 300 
mg for a period of 6 to 12 months, often combined with 2 other tuberculosta-
tic drugs to prevent drug resistance to the mycobactenae. 
In our study Isoniazid was given in a dose of 300 mg daily, but only for 3 
days during a maximum of 6 consecutive weeks. Although Isoniazid was 
administered during a maximum of only 18 days the analysis of the liver 
function tests after its administration with BCG suggested increased liver 
enzymes compared to the BCG only group. Our results indicate that even 
short-term administration of Isoniazid may impair liver function. These 
disturbances, however, are transient (data not shown). 
No significant differences in the percentage of patients with adverse events 
were found for the other side effects analyzed. Based on our 436 patients the 
study has a power of approximately 90% to detect a difference of 15% and 
a power of approximately 99% to detect a difference of 20% in the percent 
of patients with a given side effect. 
Some of our results may be influenced by the absence of a placebo in the 
patients treated by BCG alone, since knowledge of the treatment could have 
influenced the evaluation and recording of the more subjective side effects in 
the 2 treatment arms. On the other hand, the measurement of objective 
parameters, such as the liver function tests, has not been influenced by the 
trial design. Measurement of side effects remains a subjective issue because 
symptoms will be experienced differently by individual patients. Moreover, 
their importance will be assessed differently by different urologists. Some 
investigators will cease BCG-therapy in certain situations, while others will 
stimulate their patients to continue treatment because BCG is apparently 
working. The exact toxicity of BCG-therapy still remains to be defined.6 
CONCLUSIONS 
Our analysis predominantly reflects the immediate toxicity of prophylactic 
Isoniazid treatment. Most patients were treated with the 6-week induction 
course followed by 1 or more maintenance courses of three weeks. However, 
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the majority of patients have not yet reached the second or third year of 
maintenance therapy. Therefore, it is not yet possible to report the incidence 
of side effects of prophylactic Isoniazid during the full extent of 3 years of 
maintenance therapy. However, with regard to the immediate toxicity, use 
of Isoniazid as a prophylactic agent to diminish the adverse effects of 
intravesical BCG does not seem advisable. 
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INTRODUCTION 
Transitional cell carcinoma of the urinary bladder can present in two distinct 
forms, i.e. as superficial and as invasive lesion. The majority of patients 
present with the relatively benign superficial tumours (approximately 75%), 
which are limited to the mucosa (pTa) or the lamina propria (pTl).1 Carci-
noma in situ is a histological process that can also be considered superficial, 
however these lesions tend to behave more aggressive and are often found in 
association with high grade superficial tumors. 
Clinically, patients with superficial bladder cancer represent a heterogeneous 
group, some having innocuous papillary tumors that have no significant effect 
on the life expectancy of the patients whereas in other cases the tumors recur 
often and in the worst case progress to life threatening malignancies. It is the 
latter phenomenon that occurs in approximately 10% of the patient popula-
tion and is clinically most relevant. Early and accurate prediction of tumor 
progression would enable the urologist to install a more radical therapy at a 
time when it would be truly curable. 
Despite all effort undertaken to this day, the clinical and pathological 
prognostic factors are not sufficient for individualization of therapy. Clearly, 
the combination of stage, grade, tumor multiplicity and time to recurrence 
can be used to estimate the chance for recurrences and to a lesser extent of 
tumor progression.2'3 However, the specificity of these parameters is not 
sufficient. 
There is an urgent need for progression markers and now the molecular 
basis of bladder cancer development is better understood, this can be the basis 
for the design of molecular prognostic factor algorithms. In this respect 
E-cadherin and p53 immunohistochemistry are considered good candida-
tes.4·5 
So far, however, only retrospective studies indicated that p53 and E-cadherin 
immunohistochemistry can provide additional prognostic information with 
respect to the progression of superficial bladder tumors. We have prospecti-
vely followed a group of patients with superficial bladder tumors by cysto-
scopy and quantitative cytology in the period 1990-1996.6'7 Now a reason-
able number of progression events has occurred we were able to test the 
prognostic value of E-cadherin and p53 immunohistochemistry on basis of 
this prospectively recruited cohort of patients. The non-progressive patients 
were taken from the same cohort. 
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MATERIAL AND METHODS 
Tumor specimens 
The tumor specimens analyzed came from patients that were entered in a 
prospective study designed to assess the clinical utility of a quantitative 
cytological procedure termed Quanticyt™. In summary, patients with either 
a newly diagnosed superficial bladder tumor or with a history of superficial 
bladder cancer were entered in this study and followed by cystoscopy and 
quantitative cytology in the period 1990-1996.7 
Until now progression from pTa/pTl/carcinoma in situ to muscle invasive 
bladder tumors (э=рТ2) was documented for 23 patients (19 men, 4 women) 
All patients received optimal intravesical therapy. Patients were compared to 
a control group of 22 patients (20 men, 2 women) with superficial tumors, 
without progression. Tumor specimen from the group of progressive tumors 
were obtained from the pathology laboratories of the University Hospital of 
Nijmegen, The Netherlands (13 patients), the Canisius Wilhelmina Hospital 
Nijmegen, The Netherlands (5 patients) and the Rijnland Hospital 
Leiderdorp, The Netherlands (5 patients). All tumor specimen from the 
control patient group were derived from the pathology laboratory of the 
Rijnland Hospital Leiderdorp. These patients were followed for a period of 
63 till 128 months (mean of 102 months) clinically with control cystoscopies. 
From these patients, 2 tumors resected at different periods per patient were 
analyzed. The period of time between the two tissue samples taken, varied 
from 12 until 96 months (mean, 58 months). The time of diagnosis of all 
tumor tissues was from August 1985 - December 1995. 
Immediately after surgical resection, tumor specimens were fixed in a 10% 
neutral-buffered formalin solution, overnight. Following fixation, 4-цт pa­
raffin tissue sections were stained with hematoxylin and eosin. All tumors 
were histologically graded according to the WHO criteria by three-tiered 
system, identifying well, moderately and poorly differentiated tumors. Sta­
ging of tumor specimens was according to the TNM-classification. One 
paraffin block from each period, representative for tumor grade and stage 
was selected for further immunohistochemical evaluation. 
E-cadhenn and p53 immunohistochemistry 
To enhance E-cadhenn and p53 immunohistochemistry in formalin-fixed, 
paraffin-embedded bladder tumor tissues, sections were treated with micro­
wave antigen retrieval. Briefly, after deparaffinization, sections were blocked 
for endogenous peroxidase activity by incubation in 3 % hydrogen peroxidase 
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for 30 minutes at room temperature. Slides were rinsed in phosphate-buffered 
saline after each step. Sections were then submerged in 0.1 M citrate buffer, 
pH 6.0, and heated in a 800 Watt microwave on full power for 2 x 5 minutes 
cycles, pausing to ensure that there was no fluid loss due to evaporation. After 
cooling, the sections were blocked with 1% normal horse serum. For E-cad-
herin, a monoclonal antibody clone HECD-1 (Takara, Berkeley, USA) at a 
dilution of 1:50 was applied at 4°C, overnight. 
For p53, a monoclonal antibody clone D 0 7 (Neomarkers, Fremont, CA) 
at a dilution of 1:100 was applied at 4°C, overnight. A negative and positive 
control was substituted in every batch. A Vectastain Elite kit (Vector labora­
tories, Burhngame, CA) was used for peroxidase visualization. 
Scoring of E-cadhenn and p53 staining 
The light-microscopical distribution of E-cadhenn staining was classified 
according to its localization in the cell by two independent observers (TEGR, 
TWA) on two separate occasions. Normal bladder epithelium present in the 
tumor sections was used as an internal positive control. Tumors were 
classified as normal if discrete staining was present at cell-cell contacts only. 
Because the most malignant tumor cell population will ultimately determine 
the patient prognosis, we defined the presence of an aberrant (apical or 
cytoplasmic location of Ε-staining) or negative staining in more than 10% of 
the malignant cells as abnormal.8 
The accumulation of p53 was classified after semiquantitative analysis at 
a 200X magnification in the tumor's p53 hot-spot. Staining in more than 
10% of the tumor nuclei was defined abnormal. 
Statistical analysis 
For statistical analysis, the Chi-square and Fisher Exact tests for the compa­
rison between two sample percentages and in the multi variate discriminate 
analysis the Wilks method was used. A probability (p) value less than 5% 
was considered as statistically significant. Where p-values are not mentioned, 
statistical analysis was regarded not reliable due to the small sample size. 
RESULTS 
The E-Cadhenn and p53 expression in tissue specimens from 23 patients (19 
men, 4 women) with bladder tumors who progressed from superficial tumors, 
pTa, pTl and/or carcinoma in situ to muscle invasive disease, pT2 or higher 
were analyzed immunohistochemically for expression of p53 and E-cadhenn. 
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Table 1. TNM-classification at initial diagnosis. 
pTa p T l primary concomitant total 
carcinoma in carcinoma in 
situ situ 
progressive 6 15 2 6 23 
tumors 
non- 17 5 0 0 22 
progressive 
tumors 
Table 2. T u m o r grading at initial diagnosis. 
grade 1 grade 2 grade 3 carcinoma unknown total 
in situ 
progressive 3 4 12 2 2 23 
tumors 
non- 7 13 2 0 0 22 
progressive 
tumors 
This group comprised 6 pTa-tumors (26%), 15 pTl-tumors (65%), 2 primary 
carcinoma in situ (9%). In six tumors (26%), concomitant carcinoma in situ 
was observed. Histopathological grading showed 3 well differentiated (13%) 
tumors, 4 were moderately differentiated (17%) and 12 poorly differentiated 
(52%). The relative pathological stage distribution in the control group was 
as follows: pTa: 17 tumors (77%); pTl: 5 tumors (23%). These were graded 
as well differentiated tumors (32%) in 7 cases, as moderately differentiated 
(59%) in 13 patients and in 2 as poorly differentiated tumors (9%) (Table 1, 
2). 
In the group of patients with progressive disease, abnormal E-cadherin 
expression was found in 11 cases, whereas 4 tumors showed normal staining 
patterns. For technical reasons (fixation damage ) in 8 tumors the E-cadherin 
expression could not be assessed since the internal control was not positive 
(Table 3). The E-cadherin staining in the control group was more reliable, 
i.e. assessment of E-cadherin expression could be performed in 9 1 % of all 
cases that all showed normal Ε-Cadherin expression (Table 3). 
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Table 3. E-cadherin expression in progressive and non-progressive superficial bladder tumors. 
normal abnormal not évaluable total 
progressive 4 11 8 23 
non-progressive 20 0 2 22 
The p53 expression could be analyzed in all tumors. In the group of patients 
with proven progressive disease, thirteen showed an overexpression of the 
p53 protein, whereas in 10 tumors a normal p53 expression was found (Table 
4). 
The control group showed overexpression of the p53 protein in 10 tissue 
samples (45%). In 1 patient, overexpression was seen in the first tumor 
analyzed only, in 3 patients in the second tissue sample and in 3 patients (3%) 
the overexpression was determined in both tumors. A normal p53 expression 
was seen in 10 tumors (45%) and in 2 tumors the p53 status could not be 
determined since the immunohistochemistry results did not comply with 
quality control (Table 4). 
Statistical analysis of the classical tumor parameters, tumor grade, tumor 
stage and the presence of carcinoma in situ confirmed their prognostic value 
concerning the risk of tumor progression. The p-values found, were 0.0028 
for tumor grade, 0.0019 for tumor stage and 0.0023 for the presence of 
carcinoma in situ. Similarly, the presence of abnormal E-cadherin expression 
in the superficial bladder tumors could be classified as a prognostic parameter 
concerning the risk of tumor progression (p=0.00001). Hence, E-cadherin 
immunohistochemistry was the most powerful prognostic parameter. Using 
the predetermined scoring system we were unable to confirm that overexpres-
sion of p53 had prognostic value for tumor progression, (p=0.4573). 
Table 4. p53 expression assessed immunohistochemically in progressive and non progressive 
superficial TCC of the bladder. 
normal abnormal not évaluable total 
Initial 10 13 0 23 
superficial 
tumors from 
progressive cases 
Non-progressive 10 10 2 22 
tumors 
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Figure 1. Representative photomicrographs of abnormal E-cadherin and p53 immunohistoche-
mical stainings. Panel A: E-cadherin. Note the diffuse staining NOT localized at cell-cell 
contacts. Panel B: p53. Note that in the cancer area 50% of the nuclei are stained positive. 
Magnification 200 x, inset lOOOx. 
In the multivariate discriminate analysis (F-to enter=3, Wilks method) of the 
entire group, the combination of tumor grade and the presence of carcinoma 
in situ showed to be of prognostic value. The sensitivity of this combination 
was 70%, the specificity was 96%. Thus, this combination of parameters 
shows lower sensitivity and specificity than E-cadherin immunohistochemis-
try alone. 
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DISCUSSION 
The classical tumor parameters like tumor grade, tumor stage and the 
presence of carcinoma in situ are the standard prognostic factors used in the 
treatment of patients with bladder cancer. The clinical value of these para-
meters has been confirmed in this study. Unfortunately, even the combination 
of grade and the presence of carcinoma in situ identifies future tumor behavior 
only in 82% of all patients. 
New prognostic markers may be helpful in individualizing the treatment 
of patients with bladder cancer. The molecular markers E-cadhenn and p53 
have shown to have prognostic value in patients with bladder cancer.4'5 In 
the non-progressive tumor group in none of the 22 tumors studied an 
abnormal E-cadhenn expression could be detected and in the group of 23 
superficial tumors which progressed to muscle invasive disease in 15 the 
E-cadhenn status could be assessed reliably. Of these, 11 tumors showed an 
abnormal E-cadhenn expression pattern, which means that the presence of 
an abnormal E-cadhenn expression has significant prognostic value in regard 
to tumor progression (sensitivity 73%; specificity 100%). These data are in 
agreement with the data from Bnnguier et al.8 and Otto et al..9 The main 
concern is that a significant number of tumors (8/23) were not suitable for 
reliable E-cadhenn scoring, i.e. the normal urothelium was not homogene-
ously positive. Tissue fixation is likely causing this problem and recently we 
developed a new formalin fixation protocol optimized for minimal chance 
for antigen damage by overfixation. 
The p53 data are more controversial. Several retrospective studies have 
shown that p53 immunohistochemistry has prognostic value to predict the 
progression of superficial bladder cancer.10,1 ' The controversy may be explai-
ned by the fact that we decided to use a scoring system in which the threshold 
was based on the expression of p53 in normal urothelium. The score was 
based on the average number of positive nuclei (scored in ten cases) plus three 
times the standard deviation (10% of the nuclei positive). When we used 
another cutoff level similar to that of Sarkis and colleagues,1011 i.e. 25% of 
nuclei positive, there was a clear trend towards a significant prognostic value 
of p53 immunohistochemistry. This once more indicates that assessment of 
p53 status by immunohistochemistry is more finicky and standardization of 
methods and scoring system is urgently needed. This is further corroborated 
by the data of Vet et al..12 concerning the prognostic value of p53 mutation 
analysis in the same group investigated here. In that study, p53 mutations 
specifically predicted the chance for tumor progression. Moreover, the mu-
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tations were found up until 36 months prior to the manifestation of tumor 
progression. 
CONCLUSIONS 
In this analysis of patients that were prospectively followed the prognostic 
value of classical tumor parameters; tumor grade, tumor stage and the 
presence of carcinoma in situ was confirmed. In addition, abnormal E-cad-
herin expression showed to be a marker with a high potential to predict tumor 
progression, albeit that the method needs optimization on paraffin embedded 
material. Under the conditions we used, i.e. lmmunohistochemistry and a 
threshold of 10% of nuclei positive, p53 appeared to have no significant 
prognostic value. In the treatment of patients with superficial bladder cancer 
the analysis of the E-cadhenn status of the tumor can be helpful in making 
the decision when a more aggressive treatment modality has to be advised. 
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SUMMARY 
This thesis describes different studies concerning intravesical BCG immuno-
therapy to try to improve this therapy in patients with superficial bladder 
cancer. 
The rationale of this thesis is given in chapter 1. 
In chapter 2, BCG in superficial bladder cancer, consensus and controversies, 
items are discussed on which consensus has been reached as well as the 
problems which have to be solved or on which controversies exist concerning 
BCG treatment in patients with bladder cancer. The use of BCG in bladder 
cancer in man was first published by Morales et al. in 1976. This therapy 
turned out to be very successful. With the introduction of BCG therapy, many 
questions did rise, like: what is the best route of administration, which BCG 
strain is the most appropriate one, what is the best treatment schedule with 
which dose and how can the side effects observed after BCG administration 
be minimahzed. 
The most thoroughly investigated route of administration is the intravesi-
cal instillation, initially combined with percutaneous administration. At this 
moment percutaneous supportive inoculation has been abandoned. It is 
considered as not essential for the antitumor effect of BCG therapy in bladder 
cancer. In most centres intravesical administration of BCG alone is accepted 
as the best route of administration in the treatment of patients with superficial 
transitional cell cancer of the bladder. 
In searching for the appropriate BCG strain, so far the results of seven 
substrains for immunotherapy in superficial bladder cancer have been pub-
lished. These preparations are Pasteur (France), Armand-Frappier (Canada), 
Connaught (Canada), Tice (USA), Evans (UK), Moreau (Brazil) and RIVM 
(The Netherlands). Two procedures for culturing BCG bacteria for bladder 
cancer treatments are available. The mycobacteria can be grown as a pellicle 
on the surface of a liquid medium. At harvesting, the pellicle is ground in a 
ball mill to a paste. The final product of this procedure contains not only 
living BCG bacteria but also dead microorganisms and subcellular debris. 
BCG bacteria can also be grown in a homogeneously stirred deep culture 
system. This culture method results in a relatively high ratio of viable 
organisms and a small quantity of subcellular debris and dead bacilli. Most 
of the BCG preparations are surface cultured. Evans and BCG-RIVM strains 
are produced according to the homogeneous culture method. At this moment 
too few studies have been performed to reveal the best strain 
In finding the optimal treatment schedule, two basically different instillation 
schedules have been used so far. The induction scheme which consists of six 
consecutive weekly instillations and the so-called maintenance scheme The 
maintenance scheme starts with an induction course of also six consecutive 
weekly instillations followed by repeated instillations during months up to 
three years. The theory behind these repeated instillations is the assumption 
that these "booster" instillations evoke a renewed immune response against 
the tumors. Regarding the results of the reported literature, there is strong 
evidence that maintenance therapy is superior to induction therapy alone. 
To evaluate the optimal dose for BCG therapy in patients with bladder 
cancer, different studies are ongoing. At this moment no consensus has been 
reached about the question what the most optimal dose for BCG is. This also 
is the fact for the question how the toxicity of BCG treatment can be 
minimahzed. Trials in which the prophylaxis of isoniazid is used, have 
started, see chapter 6 of this thesis. 
The conclusion of chapter 2 is that although BCG has been proved to be 
very effective in the treatment of patients with superficial bladder cancer it is 
certainly not a panacea for all patients with superficial bladder cancer and 
more research is needed to answer the unsolved problems, like what is the 
optimal dose of BCG and which BCG strain is superior 
Despite the widespread use of BCG, the way in which BCG exerts its 
antitumor activity is still not well understood. The rationale of the BCG-tre-
atment is to activate the immune system, ending up in an immunological 
reaction against locally present bladder tumors cells and tumor cell degrada-
tion. To try to understand this mechanism a little better, the immunological 
products observed in the urine of superficial bladder cancer patients after 
intravesical immune therapy with BCG are studied and described in chapter 
3. In this chapter it has been shown, that after intravesical BCG 
administration in patients a local reaction of the immune system occurs. The 
number of leucocytes in the urine increases markedly. Fluorescence activated 
cell sorters (FACS) analysis of these leucocytes has revealed that in addition 
to the predominantly present granulocytes, also monocytes/macrophages and 
lymphocytes can be detected. The large number of granulocytes, which 
apparently accumulate in the urine, represent the first line of defence against 
the mycobacteria. The lymphocytes present are mainly T-lymphocytes. The 
relative numbers of cells of leukocyte sub-populations are confirmed by light 
microscopical examination. As the antitumor activity of BCG is assumed to 
be T-cell-mediated, the subset composition and activation status of the 
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lymphocytes present in the urine after intravesical BCG therapy are also 
investigated in this chapter. The T-lymphocytes are mostly of the CD4+ 
(helper/inducer) phenotype, the remainder being CD8+ (suppressor/cyto-
toxic) T-cells. NK-cells and B-cells are also present and HLA-DR antigens 
are present on the lymphocytes, indicating a high activation status of the T-
cells after intravesical BCG treatment. The induction of interleukines in the 
urine: ILI, IL2, IL6 and TNFa during intravesical BCG therapy, have been 
demonstrated. The presence of IL2 indicates activation of T-cells. ILI, IL6 
and TNFa may be produced by BCG-activated monocytes/macrophages, 
however, production by other cells cannot be excluded. In this studies peak 
concentrations of ILI, IL2, IL6 and TNFa were most frequently present in 
urine specimens collected from two to six hours after BCG instillations four 
to six. 
The conclusions of chapter 3 are that the clear increase in the number of 
granulocytes, monocytes/macropges and T-lymphocytes which were obser-
ved in the urine 24 hours after BCG instillations, indicate local activation of 
the immune system. The detection in the collected urine samples of IL2 are 
considered as the results of activation of BCG-specific T-cells. The presence 
of ILI, IL6 and TNFa might suggest activation of macrophages. 
The combination of the observed leucocytes and cytokines may play an 
important role in the antitumor activity of BCG against bladder cancer. The 
presence or absence of cytokines may also have prognostic value concerning 
the clinical response on BCG therapy. 
The analysis of immunological products in the urine of superficial bladder 
cancer patients after intravesical immunotherapy with bacillus Calmette-
Guérin contribute to understand the actual effects of the antitumor activity 
of BCG. The efficacy of BCG therapy is proven in clinical studies. However, 
it is still unknown which BCG strain is superior (see chapter 2). 
In chapter 4 the results of a randomized prospective study are reported in 
which mitomycin-C, BCG-Tice strain and BCG-RIVM strain are compared 
in patients with primary or recurrent superficial bladder tumors, including 
carcinoma in situ. The followup varies from 2 till 81 months (mean 36 
months). After a complete transurethral resection of all visible tumors the 
patients are treated with mitomycin-C (30 mg) once a week for 4 consecutive 
weeks and thereafter every month for a total of 6 months, BCG-Tice or 
BCG-RIVM (5 χ 108 colony forming units) were instilled once a week for 6 
consecutive weeks. The treatment efficacy and the incidence of side effects in 
437 patients were reported. 
I H 
The analysis of efficacy in the group of patients with papillary tumors shows 
a statistically significant difference between the treatment arms (p=0.04). The 
mitomycin-C and BCG-RIVM treatments were equally effective (p=0.53), but 
mitomycin-C treatment was more effective than BCG-Tice (p=0.01). 
For carcinoma in situ-tumors the complete response was analysed as 
parameter of efficacy. In all patients with carcinoma in situ-tumors the 
complete response was 68% (34/50) for a duration of 2 till 49 months (mean 
19 months). In the mitomycin-C-group the complete response was 67% 
(8/12), in the BCG-Tice group 74% (17/23) and in the BCG-RIVM group 
60% (9/15). These results are not statistical significant (chisquare test, 
p=0.66). 
The conclusion of this study is that 6 months of intravesical chemotherapy 
with mitomycin-C in our study is more effective in comparison with 6 weeks 
immunotherapy using BCG-Tice. Mitomycin-C causes significantly less side 
effects than both of the BCG strains. 
The use of isoniazid impaires the local immune reaction to intravesical BCG 
in the bladder of guinea pigs. In chapter 5 the effect of prophylactic given 
isoniazid in man has been investigated. Patients were treated with BCG with 
or without oral isoniazid. The concentration of free isoniazid in most urine 
samples of patients treated with BCG plus isoniazid was much higher (mean 
38.0+60.9 pg isoniazid/ml) than the minimal inhibí tory concentration (0.1 
pg isoniazid/ml), suggesting at least a bacteriostatic potential of the isoniazid 
present. However, in vitro studies showed that these urinary concentrations 
of isoniazid did not kill BCG organisms effectively, even at a concentration 
of 150 pg/ml for 24 hours. After the fifth and sixth BCG instillations a 
significant increase in the concentration of cytokines (IL2, IL6, IL8 and 
TNFa), IgG and IgA antibodies to BCG and the number of leukocytes in urine 
was observed. The leukocytes mainly consisted of granulocytes, besides 
monocytes/macrophages and, in lower amounts, T- and B-lymphocytes and 
NK-cells. The absolute number of granulocytes and the concentration of IgG 
antibodies after BCG instillation were significantly suppressed by isoniazid, 
whereas isoniazid appeared to have no effect on the urinary cytokine and IgA 
antibody concentrations or the total number and phenotype of the leukocytes 
present. 
The conclusion from this chapter indicate that isoniazid does not impair 
the local immunological stimulation after BCG instillation in man as severely 
as was observed in the guinea pig and it may be expected that isoniazid does 
not impair the antitumor efficacy of BCG. If this assumption is true and if 
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isoniazid would inhibit the potential side effects of BCG therapy, than the 
use of prophylactic isoniazid would improve treatment of intravesical BCG 
in patients with superficial bladder cancer. 
To test this hypothesis, the influence of the isoniazid on the adverse effects 
of intravesical BCG therapy in patients with superficial bladder cancer is 
studied and reported in chapter 6. The aim of this study is to analyse the 
influence of the tuberculostatic agent isoniazid on the adverse effects of 
intravesical BCG therapy. In a prospective randomized multicentre study, 
intravesical instillations with BCG-Tice and BCG-Tice plus isoniazid therapy 
were compared in patients with pTa and pTl bladder tumors. Isoniazid was 
given orally in a dose of 300 mg daily at every instillation. The purpose of 
this prophylactic administration was to reduce the side effects of BCG. 
No differences in adverse reactions after intravesical immune therapy with 
BCG could be observed between patients treated with or without prophylactic 
isoniazid therapy, neither locally nor systemically. However the analysis of 
the liver function tests after BCG plus isoniazid shows more liver toxicity 
when compared to BCG administration alone. 
The conclusion of this study is that prophylactic administration of isoni-
azid during BCG instillations provides no reduction of any of the known side 
effects of BCG. In contrast transient liver function disturbances are encoun-
tered more frequently when isoniazid is administered. The use of prophylactic 
isoniazid in patients treated with BCG is not to be recommended. 
With a more defined indication for the use of intravesical BCG therapy, the 
results will improve. The conventional prognostic parameters for patients 
with superficial bladder cancer cannot predict which tumor will behave 
aggressive in the individual patient. New tumor related markers for these 
patients are needed to help the urologist in making his decision for more 
aggressive therapy. Chapter 7 describes the value of the conventional prog-
nostic parameters and two new markers, the cell adhesion molecule E-cad-
henn and the tumor suppressor protein p53 in patients with superficial 
bladder cancer. The prognostic value of the conventional parameters was 
confirmed. The presence of an abnormal E-cadhenn expression in the bladder 
tumors showed to have a clear prognostic value concerning tumor progres-
sion (p=0.0001) and is considered as a powerful new prognostic parameter. 
The over expression of p53 protein did not show to have prognostic value 
for tumor progression in this study. 
The conclusion of chapter 7 is that in the treatment of patients with 
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superficial bladder cancer the evaluation of E-cadherin expression in the 
tumor has prognostic value and can be helpful for the urologist by making a 
decision for more aggressive therapy like BCG intravesical immunotherapy. 
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SAMENVATTING 
Patienten met oppervlakkige blaastumoren - dat wil zeggen, met tumoren die 
niet in de blaasspier ingroeien - kunnen op verschillende manieren behandeld 
worden. Een belangrijke behandelingswijze is de intravesical immunothéra-
pie met BCG. Deze therapie komt erop neer dat geprobeerd wordt het 
afweersysteem van patiënten te activeren door hun via de blaas een verzwakte 
vorm van het tuberculosebacil, het Baal Calmette-Guérin (BCG), toe te 
dienen. 
Dát oppervlakkige blaastumoren met deze therapie effectief bestreden 
kunnen worden staat vast. Over het hoe en waarom van deze behandelings-
wijze bestaat echter nog veel onduidelijkheid. Een aantal van de vragen 
waarmee deze therapie is omgeven zal in dit proefschrift worden beantwoord. 
In het inleidende hoofdstuk 1 worden de onderzoeken beschreven waarop dit 
proefschrift is gebaseerd. 
Voordat de uitkomsten hiervan worden gepresenteerd volgt in hoofdstuk 
2 eerst een overzicht van de stand van kennis. Over welke zaken bestaat in 
de wetenschappelijke literatuur overeenstemming en welke zijn nog onderhe-
vig aan discussie? 
De succesvolle toepassing van de BCG-therapie is voor het eerst beschre-
ven in 1976 door Moralis et al.. De introductie van de therapie riep evenwel 
veel vragen op: hoe kan BCG het best worden toegediend, in welke dosering, 
welke BCG-stam is het meest geschikt en hoe kunnen de bijwerkingen van de 
behandeling worden beperkt? Op deze vragen heeft het onderzoek zich nadien 
gericht. 
Van alle mogelijke toedieningsvormen is de blaasspoeling met BCG (in-
travestcale mstiliatie) het meest intensief onderzocht. Aanvankelijk werd 
toediening via de blaas gecombineerd met toediening via de huid {percutané 
toediening). Deze laatste vorm wordt nu niet meer toegepast omdat ze geen 
essentiële bijdrage bleek te leveren aan de bestrijding van blaaskanker. 
Toediening van BCG uitsluitend via de blaas wordt thans algemeen be-
schouwd als de beste aanpak. 
Behalve aan de toedieningsvorm, is veel onderzoek gewijd aan de vraag 
welke BCG-stam het meeste effect sorteert. Tot dusverre zijn zeven BCG-
stammen beproefd: de Pasteur-stam (Frankrijk), de Armand Frappier-stam 
(Canada), de Connaught-stam (Canada), de Tice-stam (Verenigde Staten), de 
Evans-stam (Verenigd Koninkrijk), de Moreau-stam (Brazilië), alsmede de 
BCG-stam die in Nederland wordt geproduceerd door het Rijksinstituut voor 
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Volksgezondheid en Milieuhygiëne (RIVM). BCG-stammen kunnen op twee 
manieren worden geproduceerd. Sommige worden gekweekt als oppervlak-
tecultuur, waarbi] zij groeien als een vlies aan de oppervlakte van een 
vloeistofmedium. Dit is de meest gangbare methode. Andere stammen, 
waaronder de Nederlandse, worden vervaardigd als een homogene cultuur. 
Welke productiewijze de beste BCG-stam oplevert is vooralsnog niet duide-
lijk. 
Ook het behandelingsschema is onderwerp van studie geweest. Tot nu 
toe zijn er twee verschillende toedieningschema's gebruikt. Enerzijds het 
inductieschema, dat bestaat uit zes wekelijkse blaasspoelingen met BCG en 
anderzijds het onderhoudsschema. Het laatstgenoemde begint eveneens met 
zes wekelijkse spoelingen, maar deze worden gevolgd door aanvullende 
instillaties gedurende een periode van enkele maanden tot drie jaar. De ratio 
van de aanvullende blaasspoelingen is dat deze werken als booster-instdlaties 
(instillaties die een versterkende werking hebben op de afweerreacties).Voor 
zover we nu weten, worden met het onderhoudsschema betere resultaten 
geboekt dan met het inductieschema. 
Wat de dosering betreft, op dit moment zijn nog diverse klinische studies 
gaande naar de vraag in welke dosering BCG het best kan worden gebruikt 
Over de manier waarop de toxiciteit (de schadelijke bijwerkingen) van de 
BCG-behandeling kan worden beperkt valt thans evenmin weinig met zeker-
heid te zeggen. Klinische studies, waarbij isoniazide (een geneesmiddel dat 
wordt gebruikt bij de behandeling van patiënten met actieve tuberculose) uit 
voorzorg wordt toegediend, zijn inmiddels van start gegaan. 
Ook over de vraag hoe BCG nu precies werkt, is het laatste woord nog 
niet gezegd. Men neemt aan dat door toediening van BCG in de blaas het 
immuunsysteem van de patient zodanig wordt geactiveerd dat er een afweer-
reactie ontstaat tegen blaastumorcellen, met als uiteindelijk gevolg de afbraak 
van de tumorcellen. 
Om meer zicht te krijgen op het verloop van het immunologische proces, is 
onderzoek gedaan naar urinemonsters van patiënten die behandeld waren 
met BCG. Hiervan wordt verslag gedaan in hoofdstuk 3. Onderzocht zijn 
verschillende in de urine aanwezige immunologische componenten, zoals 
witte bloedcellen (leucocyten), geactiveerde witte bloedcellen {lymfocyten) en 
eiwitstoffen die worden geproduceerd door lymfocyten {cytokines). 
Wat de witte bloedcellen aangaat: deze zijn bestudeerd met behulp van de 
flow cytometrische analyse, een methode waarmee cellen geselecteerd kunnen 
worden. De meest omvangrijke celpopulatie werd gevormd door poly-
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morpbenucleane granulocyten (witte bloedcellen, die granula bevatten). Deze 
reactie wordt beschouwd als een a-specifieke reactie tegen bacteneen in het 
algemeen. Daarnaast waren verschillende soorten mononucléaire leucocyten 
in de urine aanwezig, zoals: monocyten, macrofagen en T-lymfocyten. Het 
aantal leucocyten in de urine bleek toe te nemen na toediening van BCG en 
dit kan worden uitgelegd als een uiting van cellulaire afweerreacties die 
optreden in de blaaswand. 
Naast de granulocyten als grootste celpopulatie, zijn ook T-lymfocyten 
aangetoond na toediening van BCG. Omdat aangenomen wordt dat BCG 
vooral T-lymfocyten tot afweerreacties activeert, is dit celtype nader onder-
zocht. Gekeken is naar onderverdelingen binnen deze T-celpopulatie èn naar 
de staat van activiteit waarin deze lymfocyten verkeren na toediening van 
BCG. De meeste T-lymfocyten blijken van het CD4+ (helper/inducer) feno-
type te zijn, de overige van het CD8+ (supressor/cytotoxische) fenotype. 
Verder zijn in de urine natural killer cells (NK-cellen) en B-lymfocyten 
aangetoond, zij het in zeer lage concentraties. Op de lymfocyten zijn IL-2 
receptoren en HLA-DR antigenen waargenomen. Dit wijst er op dat de 
T-lymfocyten na toediening van BCG in de blaas geactiveerd zijn. 
Ook is onderzocht of er tijdens de door BCG opgewekte ontstekingreactie 
cytokines (eiwitstoffen die door lymfocyten worden gemaakt) geproduceerd 
zijn. Daarbij zijn drie soorten interleuktnes aangetoond, namelijk: ïnterleu-
kine-1 (ILI), interleukine-2 (IL2), interleukine-6 (IL6), alsmede tumornecrose 
factor-alpha (TNFct). De aanwezigheid van IL2 wijst erop dat T-lymfocyten 
zijn geactiveerd. ILI en IL6 kunnen, evenals TNFa, producten zijn van door 
BCG geactiveerde monocyten/macrofagen. Hoge concentraties van de ïnter-
leukines en van TNFa zijn het meest frequent aangetroffen in urinemonsters 
die verzameld werden gedurende twee tot zes uur na de vierde, vijfde en zesde 
blaasspoehng met BCG. 
De in hoofdstuk 3 beschreven onderzoeken leiden tot de volgende conclu-
sies Instillatie van BCG geeft een a-specifieke ontstekingsreactie, waarbij 
mogelijk ook een specifieke T-cel reactie tegen mycobacteneen ontstaat. De 
combinatie van waargenomen leucocyten en cytokines speelt waarschijnlijk 
een belangrijke rol bi) het antitumor effect van BCG bij blaastumoren. 
Mogelijk dat de aanwezigheid of afwezigheid van cytokines in de urine van 
met BCG behandelde patiënten ook een voorspellende waarde heeft voor de 
effectiviteit van de behandeling. 
Voorts blijkt de analyse van immunologische componenten in de urine van 
patiënten die behandeld zijn met BCG een vruchtbare methode te zijn om 
meer inzicht te krijgen in de werking van deze therapie. 
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In hoofdstuk 4 worden de resultaten gepresenteerd van een onderzoek dat tot 
doel had de effectiviteit van drie behandelingsmethoden van oppervlakkige 
blaastumoren te vergelijken. Het ging enerzijds om chemotherapie, waarbij 
Mitomyctne-C via de blaas werd toegediend en anderzijds om intravesical 
immunothérapie met twee verschillende BCG-stammen: de Ttce-stam en de 
RIVM-stam. Behandeld werden 437 patiënten met primaire en recidiverende 
oppervlakkige blaastumoren, inclusief patiënten met carcinoma in sttu in de 
blaas. Zij werden gevolgd gedurende een periode die varieerde tussen twee 
en 81 maanden, met een gemiddelde van 36 maanden. Na het verwijderen 
van alle zichtbare tumoren (door middel van trans urethrale resectie), kreeg 
een deel van de patiënten Mitomycine-C toegediend. Eerst éénmaal per week 
gedurende vier achtereenvolgende weken en vervolgens een maandelijkse 
blaasspoehng gedurende zes maanden. De andere patiënten werden behan-
deld met respectievelijk de Ttce-stam en de RIVM-stam. Zij kregen, geduren-
de zes achtereenvolgende weken, éénmaal per week een dosering van 5 χ IO.8 
kolonievormende eenheden van één van beide stammen toegediend. 
De vergelijking leverde de volgende resultaten op. Bij patiënten met 
papillaire tumoren bleek behandeling met Mttomycine-C meer resultaat te 
hebben dan behandeling met BCG-Ttce (het verschil is statistisch significant; 
p=0.01). De behandelingsresultaten van Mitomycine-C en BCG-RIVM ver-
toonden daarentegen geen significante verschillen. Verder konden er bij 
patiënten met carcinoma in sttu geen verschillen in effectiviteit tussen de drie 
methoden worden vastgesteld. Op grond van dit onderzoek kan worden 
geconcludeerd dat zes maanden intravesical chemotherapie met Mitomyci-
ne-C effectiever is dan de intravesical immunothérapie, waarbij gedurende 
zes weken de BCG-Ttce wordt toegediend. Een bijkomende voordeel van 
Mttomycine-C is, dat het minder bijwerkingen heeft dan beide BCG-behan-
delmgen. 
Isoniazide wordt gebruikt bij de behandeling van patiënten met actieve 
tuberculose. Op grond van theoretische inzichten valt te voorspellen dat 
preventieve toediening van Isoniazide een temperend effect kan hebben op de 
bijwerkingen van een BCG-behandehng. Maar omdat Isoniazide in feite 
bedoeld is om de BCG-bactenen te doden, kan het middel tevens van invloed 
zijn op de immunologische reactie na een BCG-behandehng. Dit laatste valt 
af te leiden uit experimenten met cavia's, die Isoniazide kregen toegediend na 
een intravesical BCG-behandehng. 
Het effect van preventieve toediening van Isoniazide op immunologische 
reacties, staat centraal in hoofdstuk 5. Een deel van de met BCG behandelde 
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patiënten kreeg wèl en een ander deel géén Isoniazide toegediend. In welk 
opzicht verschilden beide groepen van elkaar? Uit het onderzoek bleek dat de 
concentratie van het'vrije' (dat wil zeggen: niet aan een andere stof gebonden) 
Isoniazide in urinemonsters veel hoger was dan de minimale remmende 
concentratie die nodig is om tuberculosebacillen te doden (gemiddeld 38.0 ± 
60.9 pgr Isoniazid/ml). Dit zou kunnen wijzen op tenminste een bacterie 
remmende potentie van de Isoniazide in de urine. Echter, laboratoriumstudies 
hebben aangetoond dat deze concentraties van Isoniazide in de urine de 
tuberculosebacillen niet effectief doden, zelfs niet in de concentratie van 150 
pgr/ml gedurende 24 uur. 
Na de vijfde en zesde BCG-spoeling is een duidelijke toename van de 
concentratie van de cytokines (IL2, IL6, IL8 en TNFot), IgG en IgA antilicha-
men tegen BCG en het aantal leucocyten in de urine waargenomen. De 
leucocyten bestonden voornamelijk uit granulocyten en verder uit monocyten 
en macrofagenen-in kleinere aantallen-T-en B-lymfocyten alsmede natural 
killer cells. Op de cytokines, de concentratie van IgA-antilichamen, en het 
aantal of de soorten leucocyten had Isoniazide geen effect. 
Deze resultaten leiden tot de conclusie dat preventieve toediening van 
isoniazide bij mensen, anders dan bij cavia's, niet tot een verlaging van de 
afweerreactie leidt. Het is dan ook waarschijnlijk dat Isoniazide de antitumor 
effectiviteit van BCG bij de mens niet vermindert. 
Als deze veronderstelling juist is en met behulp van Isoniazide de bijwer-
kingen van een BCG-therapie kunnen worden getemperd, dan zou preventie-
ve toediening van Isoniazide een verbetering kunnen inhouden. Deze 
hypothese is klinisch getest en daarvan wordt verslag gedaan in hoofdstuk 6. 
Tijdens een onderzoek in een aantal ziekenhuizen kreeg een deel van de 
patiënten, elke keer als zij met BCG-Tice werden behandeld, ook 300 mg 
Isoniazide toegediend. Een ander deel van de patiënten kreeg alleen BCG-
Tice. Op het optreden van bijwerkingen bleek het toedienen van Isoniazide 
geen effect te hebben. De patiënten die Isoniazide kregen hadden echter wel 
meer last van leverfunctiestoornissen, al waren deze van tijdelijke aard. De 
conclusie van het onderzoek luidt dan ook dat het preventieve gebruik van 
Isoniazide geen aanbeveling verdient. 
Welke patient met een oppervlakkige blaastumor is nu gebaat bij de ïntrave-
sicale BCG-therapie en welke niet? Dat is in de klinische praktijk niet 
eenvoudig uit te maken. De traditionele indicatoren (klinische en pathologi-
sche prognostische factoren zoals: multiplicités van de tumor, recidief per-
centage van de tumor, tumorgraderingen tumorstadium), waarvan urologen 
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bij deze afweging gebruik kunnen maken, lijken weinig betrouwbaar op her 
niveau van de individuele patiënt. Er bestaat dan ook behoefte aan nieuwe 
criteria. 
In hoofdstuk 7 wordt de voorspellende waarde van conventionele indicatoren 
vergeleken met die van twee nieuwe, tumor-gerelateerde factoren: het cel-ad-
hesie molecule E-cadherine en het p53 eiwit. De uitkomst van de vergelijking 
is dat conventionele indicatoren weliswaar van voorspellende waarde zijn 
maar zeker zouden moeten worden aangevuld met een nieuwe tumor-gerela-
teerde indicator. De aanwezigheid van een abnormale E-cadherine expressie 
in het tumorweefsel bleek namelijk van duidelijk voorspellende betekenis 
voor de tumorprogressie. Een abnormale expressie van het p53 eiwit bleek 
daarentegen in dit onderzoek geen voorspellende waarde te hebben. 
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DANKWOORD 
Aan een proefschrift werk ]e nooit alleen. Er zijn zo veel mensen geweest die 
een rol hebben gespeeld bij de totstandkoming van deze dissertatie, dat ik ze 
hier onmogelijk allemaal persoonlijk kan bedanken. Toch wil ik enkele 
personen noemen die van cruciaal belang zijn geweest. 
Mijn vader zei ooit eens dat een studie pas is afgerond na de verdediging van 
het proefschrift. Als eersten wil ik daarom de professoren bedanken die mij 
enthousiast maakten voor het mooie vak van de urologie. Zij legden immers 
de basis voor dit proefschrift. Bij prof. P.W. Boer, destijds hoogleraar aan de 
Rijksuniversiteit Groningen, deed ik als student-assistent mijn eerste urolo-
gisch onderzoek. Mijn belangstelling voor de urologie was blijvend gewekt 
en nam vaste vorm aan, toen prof. dr. W.M. Moonen bereid was mij reeds 
in 1974 als nummer één te noteren op de lijst van assistenten in opleiding tot 
uroloog voor het jaar 1981. De enige voorwaarde die hij hieraan verbond 
was dat ik ieder jaar slechts één zin zou uitspreken: "Ik wil nog steeds uroloog 
worden". Des te spijtiger is het dat hij mijn promotie niet meer heeft kunnen 
meemaken. 
Dat ik uiteindelijk niet alleen uroloog wilde worden maar ook een 
proefschrift wilde schrijven, heb ik te danken aan dr. W.M. Oosterwijk en 
prof. dr. F.M.J. Debruyne. De eerste had de gave om zijn assistenten te 
enthousiasmeren voor promotieonderzoek. En met succes zoals mag blijken 
uit het feit dat bijna al mijn collega-assistenten van de chirurgische voorop-
leiding in het St. Hippolytus ziekenhuis te Delft inmiddels zijn gepromoveerd 
Prof Debruyne moedigde mij niet alleen aan dat ook te doen, maar bood mij 
in het Radboudziekenhuis van Nijmegen daartoe alle gelegenheid. 
Daarmee kon het echte werk beginnen. Dat begon met een onderzoek dat 
onvoldoende gegevens voor mijn proefschrift opleverde. Toch wil ik Ben 
Hendriks, die het dierexperimenteel onderzoek naar een diermodel voor het 
testen van chemotherapie bij blaaskanker uitvoerde, op deze plaats bedanken. 
Zijn inspanningen leidden in 1985 wel tot een artikel voor het tijdschrift 
American journal of pathology. 
Het was mijn co-promotor dr. A.P.M van der Meijden die mij ervan over-
tuigde dat het toch mogelijk moest zijn om als perifeer werkend uroloog 
voldoende gegevens te verzamelen om een proefschrift te schrijven. Hoewel 
ik niet meer verbonden was aan het Radboudziekenhuis te Nijmegen, maar 
werkte in het Rijnlandziekenhuis in Leiderdorp, werd ik in de gelegenheid 
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gesteld te participeren in de studiegroep van urologen werkzaam in het zuiden 
en oosten van Nederland: the Dutch South East Cooperative Urological 
Group. 
Samen met mijn tweede co-promotor dr. P.A. Steerenberg van het Rijksin-
stituut voor de Volksgezondheid en Milieuhygiëne, spraken we uren over de 
nieuwe opzet van mijn proefschrift. 
Veel van de gegevens voor het onderzoek zijn verzameld op de polikliniek 
van de afdeling urologie van het Rijnlandziekenhuis, waar we patiënten die 
leden aan oppervlakkige blaastumoren, behandelden met BCG. De zorgvul-
digheid die de medewerkers van de polikliniek urologie betrachtten bij het 
verzamelen van de urine, maakte het mogelijk genoeg gegevens te vergaren. 
Om in het proefschrift ook een hoofdstuk op te kunnen nemen waaraan 
meer basisresearch ten grondslag ligt, verleende prof. dr. J.A. Schalken zijn 
medewerking. Met hem onderzochten we of een tumor gerelateerde parame-
ter een betere voorspellende waarde had dan de conventionele tumorparame-
ters. In hoofdstuk zeven hebben we dit kunnen aantonen. 
Dr. H.F.M. Karthaus, uroloog, verbonden aan het Canisius Wilhelmina-
ziekenhuis te Nijmegen, heeft zich ingespannen om ook vanuit zijn kliniek 
gegevens aan te leveren voor de basisresearch in het kader van het onderzoek 
naar tumor gerelateerde tumormarkers. Behalve voor deze gegevens, ben ik 
hem dank verschuldigd voor zijn inzet om de promotie nog in 1997 te kunnen 
laten plaatsvinden. 
Mijn dank gaat ook uit naar drs. W.H. Doesburg. Hij is verbonden aan 
de afdeling Medische Statistiek van het Academisch Ziekenhuis Nijmegen St. 
Radboud en stond altijd klaar om statistische bewerkingen uit te voeren. 
Het schrijven van een proefschrift vraagt niet alleen de medewerking van 
collega's, maar ook die van personen uit de naaste omgeving. 
Ik dank mijn ouders voor de optimale coaching van jongs af aan, waardoor 
ik medicijnen kon studeren in Groningen en mij later kon specialiseren. 
Dezelfde stimulans heb ik mogen ervaren bij het schrijven van mijn proef-
schrift. 
Ook mijn schoonouders - die als naaste buren van ons eerste huisje nauw 
betrokken waren bij de start van mijn wetenschappelijk onderzoek - wil ik 
dankzeggen voor hun enthousiasmerende invloed. Helaas heeft mijn schoon-
vader, prof. dr. Th.J.G. van Rens, de realisatie van dit proefschrift niet meer 
mogen meemaken. Omdat hij er echter van overtuigd was dat ik het zou 
voltooien, formuleerde hij in zijn laatste dagen een stelling voor mijn proef-
schrift. 
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Carien Nelissen en Jaap van Donselaar, onze vrienden in Leiderdorp met wie 
Tina en ik vele avonden het mooie spel Mah-jongg spelen, hebben mi] 
geholpen bij de Nederlandse samenvatting en de lay-out van het proefschrift. 
Als laatste wil ik mijn vrouw Titia bedanken die mij zowel geestelijk als 
praktisch (typewerk!) terzijde heeft gestaan. 
Lieve Titia, dit boekje heeft veel geduld van je geeist. Je ontvluchtte zelfs 
het huis als ik behoefte had om rustig te schrijven. Het was niet altijd 
gemakkelijk. Toch heb JIJ mi) vanaf het begin gesteund en gestimuleerd. Nu 
het werk gedaan is, verheug ik me erop dat we meer tijd voor elkaar en voor 
ons gezin zullen hebben. 
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STELLINGEN 
behorend bi) het proefschrift 
IMPROVEMENTS OF BCG-IMMUNOTHERAPY 
IN SUPERFICIAL BLADDER CANCER 
van Peter D.J. Vcgt 
Nijmegen, 16 september 1997 
1. Intravesical immunothérapie met BCG is effectief ten aanzien van het 
voorkomen van recidief blaastumoren alsmede de behandeling van op-
pervlakkige blaastumoren. 
Dit proefschrift. 
2. Analyse van immunologische producten in de urine van patiënten na 
intravesicale BCG-toediening kunnen de inzichten in het werkings-
mechanisme van de antitumoractiviteit van BCG verruimen. 
Dit proefschrift. 
3. Intravesicale chemotherapie is bij bepaalde oppervlakkige blaastumoren 
even effectief als intravesicale immunothérapie. 
Dit proefschrift. 
4. Het nut van het adjuvant toedienen van Isoniazid ter vermindering van 
de bijwerkingen van intravesicale immunothérapie is niet aangetoond. 
Dit proefschrift. 
5. Profylactisch toedienen van Isoniazid tijdens de behandeling met BCG 
geeft passagière leverfunctiestoornissen. 
Dit proefschrift. 
6. Kwantitatieve cytologie (Quanticyt) is een waardevol onderzoek bij de 
followup van patiënten met oppervlakkige blaastumoren. 
7. Een abnormale E-cadherin expressie in blaastumorweefsel is een prog-
nostische tumormarker met een hoge specificiteit ten aanzien van de kans 
op tumorprogressie. 
Dit proefschrift. 
8. Met de toegenomen mogelijkheden voor de medicamenteuze behandeling 
van obstructieve prostaatklachten zijn de resultaten van de operatieve 
therapieën bij patiënten met deze klachten verbeterd. 
9. Het roken van sigaretten bevordert het ontstaan van blaaskanker. 
10. Omdat een voorste kruisband in het kniegewricht een natuurlijke intrin-
sieke torsie heeft, zal voor een zo optimaal mogelijk resultaat van een 
voorste kruisbandreconstructie de te plaatsen nieuwe kruisband eveneens 
getordeerd moeten worden. 
Prof. dr. Th.J.G. van Rens. 
11. Voor het adequaat kunnen functioneren van een Vereniging Medische 
Staf in een ziekenhuis is een kernstaf met gemandateerde leden een 
vereiste. 
12. Een coöperatieve vereniging van vrijgevestigde medisch specialisten is een 
noodzakelijk kwaad. 
13. Promoveren kun je leren. 
Dr. P.A. Vegt. 
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